

CITATION REPORT

List of articles citing

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

DOI: 10.1056/nejm200104053441401

New England Journal of Medicine, 2001, 344, 1031-7.

Source: <https://exaly.com/paper-pdf/32293133/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2255	.		
2254	Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. 2001 , 293, 876-80		2666
2253	Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. <i>New England Journal of Medicine</i> , 2001 , 344, 1038-42	59.2	2309
2252	The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. 2001 , 14, 497-529		112
2251	Imatinib. 2001 , 61, 1765-74; discussion 1775-6		52
2250	Are the insulin-like growth factors relevant to cancer?. 2001 , 11, 339-45		12
2249	Chronic myelogenous leukemia. 2001 , 286, 895-8		48
2248	STI-571 active and well tolerated in CML and ALL. 2001 , &NA;, 7		
2247	Imatinib Mesylate:. 2001 , 9, 263-265		
2246	Clinical syndromes of transformation in clonal hematologic disorders. 2001 , 111, 480-8		3
2245	New molecular targets and biological therapies in sarcomas. 2001 , 27, 317-26		19
2244	[Chronic myeloid leukemia and tyrosine kinase inhibitors]. 2001 , 22, 894-9		2
2243	Translational research--traffic on the bridge. 2001 , 55, 565-71		9
2242	Chromosomal translocations in sarcomas: prospects for therapy. 2001 , 7, 554-9		35
2241	STI571: a magic bullet?. 2001 , 37, 1816-9		32
2240	Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. 2001 , 38, 9-14		31
2239	Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. 2001 , 38, 15-21		15

2238	Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. 2001 , 38, 22-7	22
2237	Perspectives on the future of chronic myeloid leukemia treatment. 2001 , 38, 35-42	9
2236	Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. 2001 , 358, 1421-3	1091
2235	Imatinib for chronic myeloid leukaemia: a NICE mess. 2001 , 358, 1478	7
2234	A "bureausceptic" view of cancer drug rationing. 2001 , 358, 1660	2
2233	Imatinib for chronic myeloid leukaemia: a NICE mess. 2001 , 358, 1902	1
2232	Imatinib for chronic myeloid leukaemia: a NICE mess. 2001 , 358, 1903	8
2231	Targeted therapies for high-risk acute myeloid leukemia. 2001 , 15, 677-701, viii-ix	4
2230	Exploiting genetic alterations to design novel therapies for cancer. 2001 , 15, 657-75, viii	8
2229	Innovative cancer drug targets: genomics, transcriptomics and clinomics. 2001 , 2, 911-5	7
2228	Retinoid therapy of childhood cancer. 2001 , 15, 867-910	90
2227	Clinical news update. 2001 , 6, 211-213	
2226	Síndromes mieloproliferativos. Leucemia mieloide crónica. 2001 , 8, 2755-2763	
2225	Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. 2001 , 33, 451-5	82
2224	New developments in the urokinase-type plasminogen activator system. 2001 , 5, 711-722	10
2223	Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. 2001 , 98, 13790-5	2003
2222	Alemtuzumab/Arsenic Trioxide/Imatinib Mesylate. 2001 , 36, 930-935	
2221	The Oncologic Four-Minute Mile. 2001 , 6, 230-232	14

2220	Angiogenesis Research: Guidelines for Translation to Clinical Application. 2001 , 86, 23-33	203
2219	The Impact of Whole Genome Sequence Data on Drug Discovery A Malaria Case Study. 2001 , 7, 698-710	22
2218	[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology]. 2001 , 24 Suppl 5, 65-71	2
2217	Current management of soft tissue sarcomas. 2001 , 12, 505-508	4
2216	Trends in transplantation of hematopoietic stem cells from unrelated donors. 2001 , 8, 337-41	14
2215	Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. 2001 , 98, 1773-81	53
2214	The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. 2001 , 98, 3205-11	27
2213	Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. 2001 , 98, 3541-53	110
2212	Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. 2001 , 98, 3864-7	75
2211	Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. 2001 , 98, 1732-8	201
2210	Chronic myeloid leukemia: current treatment options. 2001 , 98, 2039-42	178
2209	Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. 2001 , 98, 2808-16	93
2208	New approaches to lymphoma diagnosis. 2001 , 2001, 194-220	60
2207	Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. 2001 , 203, 57-9	83
2206	Improving the management of chronic myeloid leukaemia. 2001 , 62, 553-5	
2205	Gastrointestinal stromal tumors. 2001 , 8, 252-61	67
2204	[Chronic myeloproliferative disorders. The new WHO classification]. 2001 , 22, 429-43	10
2203	Gastrointestinal stromal tumors. 2001 , 2, 485-91	59

2202 In response to Dr. Vriesendorp. **2001**, 51, 281-282

2201 Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. **2001**, 115, 569-74 55

2200 Small molecule: large hopes. **2001**, 31, 382-3

2199 Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity. **2001**, 11, 3091-4 26

2198 Pharmacoepidemiology and drug safety. **2001**, 10, 467-82 1

2197 Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. **2001**, 92, 2501-7 19

2196 Bibliography. Current awareness in hematological oncology. **2001**, 19, 159-66

2195 Cancer: the evolved consequence of a destabilized genome. **2001**, 23, 1037-46 53

2194 Molecular and physiologic mechanisms of drug resistance in cancer: an overview. **2001**, 20, 1-2 24

2193 Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. **2001**, 20, 6793-804 70

2192 Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. **2001**, 28, 721-4 24

2191 Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. **2001**, 15, 1001-10 107

2190 Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571. **2001**, 15, 1795-7 20

2189 Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. **2001**, 15, 1823-33 63

2188 Modeling Philadelphia chromosome positive leukemias. **2001**, 20, 5644-59 59

2187 The hunting of the Src. **2001**, 2, 467-75 499

2186 Oncogenic kinase signalling. **2001**, 411, 355-65 3016

2185 New-age drug meets resistance. **2001**, 412, 281-2 54

2184	Rescuing the function of mutant p53. 2001 , 1, 68-76	466
2183	Cancer gene therapy: fringe or cutting edge?. 2001 , 1, 130-41	284
2182	Chromosome segregation and cancer: cutting through the mystery. 2001 , 1, 109-17	341
2181	Comprehensive cancer centres and the war on cancer. 2001 , 1, 240-5	9
2180	Signaling pathways in apoptosis as potential targets for cancer therapy. 2001 , 11, 343-8	58
2179	Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. 2001 , 67, 302-8	49
2178	The role of semaphorins in lung cancer. 2001 , 3, 145-50	10
2177	Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. 2001 , 93, 1830-2	78
2176	Imatinib mesylate: a new pill for chronic myelogenous leukemia. 2001 , 9, 263-5	3
2175	Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention, and Cancer Therapy: July 15-18, 2001, The Gant Conference Center, Aspen, Colorado. 2001 , 29, 677-717	
2174	Chronic myelogenous leukemia. 2001 , 2001, 87-112	65
2173	Molecular basis of mature T-cell leukemia. 2001 , 286, 2308-14	51
2172	Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2001 , 344, 1084-6	59.2 206
2171	How do tumors make ends meet?. 2001 , 98, 12331-3	23
2170	Selected novel anticancer treatments targeting cell signaling proteins. 2001 , 6, 517-37	58
2169	Roots of clinical resistance to STI-571 cancer therapy. 2001 , 293, 2163	204
2168	A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular endothelial growth factor expression. 2001 , 93, 734-5	34
2167	Cutaneous reactions to STI571. <i>New England Journal of Medicine</i> , 2001 , 345, 618-9	59.2 130

2166	Management of small cell lung cancer. 2001 , 1, 197-210		1
2165	Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. <i>New England Journal of Medicine</i> , 2001 , 344, 1052-6	59.2	1601
2164	Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. 2001 , 98, 3569-74		224
2163	92nd Annual Meeting of the American Association for Cancer Research. 24-28 March, 2001, New Orleans, Louisiana, USA. 2001 , 10, 1173-93		2
2162	Therapy-related changes of CD34+ progenitor cells in chronic myeloid leukemia: a morphometric study on sequential trephine biopsies. 2001 , 10, 827-36		1
2161	Drugs targeted against protein kinases. 2001 , 6, 303-15		25
2160	Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB. 2002 , 13, 2051-64		22
2159	Clinical trial design for target-based therapy. 2002 , 7, 401-9		127
2158	Nonmyeloablative allogeneic hematopoietic stem cell transplantation. 2002 , 11, 243-63		13
2157	High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration. 2002 , 11, 293-300		6
2156	Medical management of breast cancer: today and tomorrow. 2002 , 17, 137-49		9
2155	Lung Cancer. 2002 ,		
2154	Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. 2002 , 20, 3691-702		94
2153	Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. 2002 , 277, 8076-82		80
2152	Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies. 2002 , 20, 1692-1703		273
2151	Cautious arguments in favor of body surface area-based dosing. 2002 , 20, 4270; author reply 4270-1		2
2150	Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. 2002 , 99, 10700-5		230
2149	Hypersensitivity pneumonitis related to imatinib mesylate. 2002 , 20, 4271-2		59

2148	Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. 2002 , 99, 381-3	103
2147	Recent advancements in the treatment of chronic myelogenous leukemia. 2002 , 53, 369-81	63
2146	Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease. 2002 , 86, 1333-5	7
2145	Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. 2002 , 99, 2304-9	65
2144	The roles of FLT3 in hematopoiesis and leukemia. 2002 , 100, 1532-42	1128
2143	Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. 2002 , 107, 64-75	64
2142	Cytogenetic and molecular genetic aspects of essential thrombocythemia. 2002 , 108, 55-65	47
2141	History of pediatric hematology oncology. 2002 , 52, 979-92	24
2140	The impact of chip technology on cancer medicine. 2002 , 13 Suppl 4, 109-13	4
2139	Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. <i>New England Journal of Medicine</i> , 2002 , 347, 481-7	59.2 546
2138	BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. 2002 , 100, 3041-4	271
2137	Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. 2002 , 1, 674-82	21
2136	Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. 2002 , 277, 32214-9	126
2135	Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. 2002 , 117, 188-93	263
2134	ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. 2002 , 117, 360-7	59
2133	Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. 2002 , 17, 685-7	34
2132	Chronic Myelogenous Leukemia. 2002 , 33, 203-207	
2131	Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. 2002 , 16, 455-62	199

2130	The emergence of resistance to targeted cancer therapeutics. 2002 , 3, 603-23		21
2129	Medical events during airline flights. <i>New England Journal of Medicine</i> , 2002 , 347, 535-7; author reply 535-7	59.2	8
2128	Transfusion medicine. <i>New England Journal of Medicine</i> , 2002 , 347, 538-9; author reply 538-9	59.2	1
2127	n-3 fatty acids and the risk of sudden death. <i>New England Journal of Medicine</i> , 2002 , 347, 531-3; author reply 531-3	59.2	5
2126	Hematogenous anaerobic osteomyelitis. <i>New England Journal of Medicine</i> , 2002 , 347, 533; author reply 533	59.2	
2125	Treatment preferences of seriously ill patients. <i>New England Journal of Medicine</i> , 2002 , 347, 533-5; author reply 533-5	59.2	1
2124	Framework Convention on Tobacco Control. <i>New England Journal of Medicine</i> , 2002 , 347, 537-8; author reply 537-8	59.2	
2123	Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. <i>New England Journal of Medicine</i> , 2002 , 347, 539-40	59.2	32
2122	[Growth factors in otorhinolaryngology]. 2002 , 81 Suppl 1, S39-60		1
2121	Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results. 2002 , 29, 1-8		14
2120	Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. 2002 , 16, 549-58		104
2119	Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells. 2002 , 43, 703-9		34
2118	Chapter 23. Tumor classification for tailored cancer therapy. 2002 , 37, 225-236		
2117	Perspective: lessons learned from molecular genetic studies of thyroid cancer--insights into pathogenesis and tumor-specific therapeutic targets. 2002 , 143, 2025-8		46
2116	Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. 2002 , 16, 573-80		19
2115	The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. 2002 , 16, 486-507		211
2114	[Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells]. 2002 , 127, 2205-7		29
2113	Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. 2002 , 16, 393-9		35

2112	STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. 2002 , 16, 570-2	37
2111	Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. 2002 , 16, 1154-9	8
2110	Unusual pulmonary lesions: endobronchial carcinoid of the lung. 2002 , 20, 4269; author reply 4269-70	
2109	Gastrointestinal stromal tumours (GIST): biology and treatment. 2002 , 13 Suppl 4, 287-9	44
2108	Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. 2002 , 94, 1673-9	82
2107	Views of American oncologists about the purposes of clinical trials. 2002 , 94, 1847-53	84
2106	Oral lichenoid reaction to imatinib (STI 571, Gleevec). 2002 , 205, 169-71	43
2105	The impact of future technology on cancer care. 2002 , 2, 560-8	19
2104	Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia. 2002 , 300, 1075-84	8
2103	Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-alpha and -beta during human testicular development and disease. 2002 , 87, 2310-9	83
2102	Drugs, aging, and the future. 2002 , 57, M2-6	8
2101	Multifaceted approach to the treatment of bcr-abl-positive leukemias. 2002 , 7 Suppl 1, 30-8	23
2100	Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia. 2002 , 20, 656-664	41
2099	Reduced intensity conditioning and allogeneic stem-cell transplantation: determining its role in multiple myeloma. 2002 , 20, 4268; author reply 4268-9	5
2098	Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. 2002 , 168, 466-74	223
2097	The Role of the RET Protooncogene in Multiple Endocrine Neoplasia Type 2. 2002 , 1067-1078	
2096	Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa. 2002 , 20, 214-220	58
2095	Current World Literature. 2002 , 5, 333-355	

2094	STI571 (imatinib mesylate): the tale of a targeted therapy. 2002 , 13, 111-4	10
2093	Pathophysiology of nervous system diseases. 2002 , 3-13	
2092	Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. 2002 , 14, 10-8	39
2091	CD117 (KIT receptor) expression in Merkel cell carcinoma. 2002 , 24, 289-93	102
2090	Genomic approaches to the pathogenesis and treatment of acute lymphoblastic leukemias. 2002 , 9, 339-44	8
2089	CD117 (KIT): a diverse protein with selective applications in surgical pathology. 2002 , 9, 65-9	54
2088	Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. 2002 , 9, 303-7	88
2087	Unexpected pleural effusions in 3 pediatric patients treated with STI-571. 2002 , 24, 694-5	27
2086	Applications of advances in molecular biology and genomics to clinical cancer care. 2002 , 25, 110-22; quiz 123-4	5
2085	Role of FLT3 in leukemia. 2002 , 9, 274-81	156
2084	C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. 2002 , 26, 486-92	130
2083	Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. 2002 , 100, 3877-86	127
2082	Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. 2002 , 100, 435-41	98
2081	Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. 2002 , 100, 635-9	263
2080	Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. 2002 , 100, 1068-71	224
2079	FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. 2002 , 99, 310-8	403
2078	Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. 2002 , 99, 3547-53	251
2077	Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. 2002 , 99, 3861-2	71

2076	A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. 2002 , 99, 3885-91	401
2075	BCR-ABL-induced adhesion defects are tyrosine kinase-independent. 2002 , 99, 4122-30	64
2074	Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. 2002 , 99, 664-71	100
2073	Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. 2002 , 99, 713-5	72
2072	Oligodeoxynucleotide-mediated inhibition of c-myc gene expression in autografted bone marrow: a pilot study. 2002 , 99, 1150-8	65
2071	Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2. 2002 , 99, 1388-97	58
2070	A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. 2002 , 99, 1527-35	147
2069	Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. 2002 , 99, 1766-75	62
2068	Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. 2002 , 99, 1860-2	215
2067	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. 2002 , 99, 1928-37	850
2066	Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. 2002 , 99, 1971-7	168
2065	Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. 2002 , 99, 3465-7	51
2064	High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. 2002 , 99, 3472-5	582
2063	Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. 2002 , 99, 3854-6	65
2062	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. 2002 , 99, 3530-9	986
2061	A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. 2002 , 100, 1965-71	480
2060	Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. 2002 , 100, 1088-91	110
2059	Current trends in hematopoietic stem cell transplantation in Europe. 2002 , 100, 2374-86	172

2058	The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. 2002 , 100, 1628-33	114
2057	Heat-shock protein 90: potential involvement in the pathogenesis of malignancy and pharmacological intervention. 2002 , 25, 466-73	11
2056	Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. 2002 , 7, 143-9	24
2055	Cancer vaccines for hematologic malignancies. 2002 , 9, 138-51	18
2054	The Impact of Biomarkers and Surrogate End Points on Regulatory Approval of New Drugs. 2002 , 2, 235-245	
2053	Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. 2002 , 128, 875-9	18
2052	Chronic myelogenous leukemia. 2002 , 2002, 111-35	64
2051	Evolution of anticancer drug discovery and the role of cell-based screening. 2002 , 94, 78-9	66
2050	Imatinib mesylate--a new oral targeted therapy. <i>New England Journal of Medicine</i> , 2002 , 346, 683-93	59.2 676
2049	Genetics of myeloid leukemias. 2002 , 3, 179-98	386
2048	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. 2002 , 45, 3772-93	111
2047	Endothelial IKK beta signaling is required for monocyte adhesion under laminar flow conditions. 2002 , 34, 349-59	16
2046	Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. 2002 , 28, 75-85	45
2045	Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. 2002 , 28, 361-72	26
2044	Microarrays in pharmacogenomics--advances and future promise. 2002 , 3, 589-601	37
2043	Chapter 26. To market, to market - 2001. 2002 , 37, 257-277	17
2042	Minimal residual disease in chronic myeloid leukaemia patients. 2002 , 15, 159-78	14
2041	Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia. 2002 , 15, 91-103	8

2040	Molecular remission and non-Hodgkin's lymphoma. 2002 , 15, 549-62		7
2039	Acute lymphoblastic leukaemia: diagnosis and classification. 2002 , 15, 597-621		38
2038	Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts. 2002 , 15, 757-69		16
2037	T-cell activation through the antigen receptor. Part 2: role of signaling cascades in T-cell differentiation, anergy, immune senescence, and development of immunotherapy. 2002 , 109, 901-15		81
2036	Intestinal bleeding due to a stromal tumor in a Meckel's diverticulum. 2002 , 56, 147-9		8
2035	Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. 2002 , 132, 960-6; discussion 966-7		94
2034	Megakaryocytic blast crisis as a first presentation of chronic myeloid leukemia. 2002 , 69, 58-61		16
2033	Antimetastatic drugs in prostate cancer. 2002 , 1, 14-9		7
2032	Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. 2002 , 108, 180-202		79
2031	Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. <i>New England Journal of Medicine</i> , 2002 , 347, 472-80	59.2	3474
2030	Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. <i>New England Journal of Medicine</i> , 2002 , 346, 645-52	59.2	1693
2029	Role of receptor tyrosine kinases in lung cancer. 2003 , 74, 113-25		12
2028	Mechanistic and genetic studies of radiation tumorigenesis in the mouse--implications for low dose risk estimation. 2002 , 22, A11-6		7
2027	BCR/ABL. 2002 , 199-204		
2026	Biology and therapeutic potential of the interleukin-4/interleukin-13 signaling pathway in asthma. 2002 , 1, 185-93		43
2025	Oral Chemotherapy for the Older Patient with Cancer. 2002 , 1, 101-108		9
2024	Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring. 2002 , 4, 1-10		19
2023	Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. 2002 , 43, 2281-9		11

2022	The search for optimal treatment in relapsed and refractory acute myeloid leukemia. 2002 , 43, 281-91	27
2021	Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia. 2002 , 43, 2413-5	13
2020	Targeting apoptosis in cancer chemotherapy. 2002 , 6, 73-84	33
2019	New drugs, new drug resistance mechanisms. 2002 , 2, 239-40	0
2018	Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. 2002 , 60, 115-21; discussion 122	40
2017	The conformational plasticity of protein kinases. 2002 , 109, 275-82	1355
2016	Resistance to targeted therapy in leukaemia. 2002 , 359, 458-9	19
2015	Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. 2002 , 359, 481-6	189
2014	BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. 2002 , 359, 487-91	404
2013	Treatment of hypereosinophilic syndrome with imatinib mesilate. 2002 , 359, 1577-8	273
2012	Cerebral oedema as a possible complication of treatment with imatinib. 2002 , 359, 1751-2	45
2011	Not so NICE for CML. 2002 , 359, 2036	3
2010	Realising the potential of targeted therapies in oncology. 2002 , 360, 424-5	1
2009	Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. 2002 , 21, 8804-16	119
2008	Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. 2002 , 93, 849-56	47
2007	Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer. 2002 , 38 Suppl 2, S37-43	19
2006	Molecular markers in colorectal cancer. 2002 , 359, 183-4	6
2005	Clinical management of gastrointestinal stromal tumors: before and after STI-571. 2002 , 33, 466-77	482

2004	Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. 2002 , 33, 1182-7	78
2003	Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. 2002 , 39, 18-21	19
2002	Chronic myeloid leukemia: current therapies and the potential role of farnesyltransferase inhibitors. 2002 , 39, 11-7	12
2001	Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. 2002 , 39, 26-30	16
2000	Advancing the treatment of hematologic malignancies through the development of targeted interventions. 2002 , 39, 1-5	10
1999	Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. 2002 , 39, 32-7	38
1998	Biomedical technology revolution: opportunities and challenges for oral and maxillofacial surgeons. 2002 , 31, 1-12	20
1997	Acute myelogenous leukemia: advances and limitations of treatment. 2002 , 93, 257-63	14
1996	Impact of the Human Genome Project on the clinical management of sporadic cancers. 2002 , 3, 349-56	11
1995	Management of malignant gastrointestinal stromal tumours. 2002 , 3, 655-64	427
1994	Using cancer genetics to guide the selection of anticancer drug targets. 2002 , 2, 366-73	39
1993	Receptor tyrosine kinases as targets for anticancer drugs. 2002 , 8, 17-23	196
1992	STI571 (Gleevec) as a paradigm for cancer therapy. 2002 , 8, S14-8	197
1991	Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. 2002 , 1, 13-5	42
1990	Perspectives on the development of a molecularly targeted agent. 2002 , 1, 31-6	225
1989	PDGF and the testis. 2002 , 13, 11-7	42
1988	Rational therapeutic intervention in cancer: kinases as drug targets. 2002 , 12, 111-5	113
1987	From molecular changes to customised therapy. 2002 , 38, 333-8	29

1986	Tyrosine kinases as targets for cancer therapy. 2002 , 38 Suppl 5, S11-8	74
1985	Imatinib: a selective tyrosine kinase inhibitor. 2002 , 38 Suppl 5, S19-27	181
1984	Pharmacology of imatinib (STI571). 2002 , 38 Suppl 5, S28-36	180
1983	Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). 2002 , 38 Suppl 5, S52-9	88
1982	Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts. 2002 , 38 Suppl 5, S66-9	6
1981	Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. 2002 , 38 Suppl 5, S70-6	25
1980	Imatinib: the first 3 years. 2002 , 38 Suppl 5, S77-82	29
1979	Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. 2002 , 38 Suppl 5, S83-7	170
1978	Hereditary cancer: family history, diagnosis, molecular genetics, ecogenetics, and management strategies. 2002 , 84, 3-17	14
1977	FLT3 in human hematologic malignancies. 2002 , 43, 1541-7	59
1976	Matrix metalloproteinase inhibitors and cancer: trials and tribulations. 2002 , 295, 2387-92	2274
1975	Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. 2002 , 99, 3792-800	224
1974	Pediatric oncology: current views and outcomes. 2002 , 49, 1305-18, vii	20
1973	Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. 2002 , 16, 1115-24	48
1972	[New therapeutic targets and strategies in lung cancer]. 2002 , 38, 386-91	5
1971	Medical oncology. 2002 , 176, 25	
1970	Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. 2002 , 100, 1590-1595	135
1969	Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. 2002 , 100, 1910-1912	46

1968	Erratum for vol. 98, p. 2326. 2002 , 99, 1535-1535	1
1967	Improved disease-free survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. 2002 , 99, 1130-1135	69
1966	Making Sense of the Epithelial Barrier: What Molecular Biology and Genetics Tell Us About the Functions of Oral Mucosal and Epidermal Tissues. 2002 , 66, 564-574	91
1965	Pityriasis rosea associated with imatinib (STI571, Gleevec). 2002 , 205, 172-3	35
1964	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. 2002 , 20, 656-64	69
1963	Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. 2002 , 20, 354-5	14
1962	STI571: a paradigm of new agents for cancer therapeutics. 2002 , 20, 325-34	159
1961	Human bone marrow myeloma cells express RANKL. 2002 , 20, 353-4	92
1960	Imatinib mesylate. 2002 , 6, 118-20	
1959	Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. 2002 , 20, 1692-703	497
1958	Autoinhibitory mechanisms in receptor tyrosine kinases. 2002 , 7, d330-40	30
1957	Radiation recall dermatitis from high-dose interferon alfa-2b. 2002 , 20, 355-7	27
1956	Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. 2002 , 20, 214-20	103
1955	Imatinib mesylate, the first molecularly targeted gene suppressor. 2002 , 22, 1249-65	12
1954	Role of small-molecule kit receptor tyrosine kinase inhibitors in the treatment of small-cell lung cancer. 2002 , 3, 213-8	9
1953	New insights into the molecular actions of serotonergic antimigraine drugs. 2002 , 94, 77-92	56
1952	Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. 2002 , 93, 79-98	253
1951	Family with acute myelocytic leukemia, breast, ovarian, and gastrointestinal cancer. 2002 , 137, 8-14	6

1950	Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. gastrointestinal stromal tumors. 2002 , 135, 1-22	38
1949	BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. 2002 , 139, 30-3	64
1948	CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). 2002 , 1, 421-32	278
1947	Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. 2002 , 1, 413-5	116
1946	Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. 2002 , 2, 117-25	1402
1945	Acute leukemia: a pediatric perspective. 2002 , 2, 437-45	57
1944	Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. 2002 , 12, 1386-94	27
1943	In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. 2002 , 30, 729-37	90
1942	Surrogate endpoints in cancer drug development. 2002 , 7, 951-6	15
1941	Protein tyrosine kinases: autoregulation and small-molecule inhibition. 2002 , 12, 735-41	70
1940	Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. 2002 , 70, 149-53	22
1939	Amyloidoma of lymph node. 2002 , 70, 177-9	6
1938	Lichenoid eruption to STI 571. 2002 , 70, 179	4
1937	Adult T-cell leukemia with cyclic neutropenia in a seronegative patient carrying only the tax gene of HTLV-I. 2002 , 71, 137-8	4
1936	Chronic lymphocytic lymphoma and multiple myeloma in a patient infected with human herpesvirus 8 (HHV-8). 2002 , 71, 138-9	1
1935	Allografting of peripheral blood stem cell mobilized from a donor developing herpes zoster virus infection. 2002 , 71, 140-1	1
1934	Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. 2002 , 71, 139-40	16
1933	CML after treatment for lymphoid malignancy: Therapy-related CML or coincidence?. 2002 , 71, 139	10

1932	Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. 2002 , 71, 184-90	6
1931	Hereditary chronic lymphocytic leukemia: an extended family study and literature review. 2002 , 115, 113-7	15
1930	Derangement of growth and differentiation control in oncogenesis. 2002 , 24, 83-90	24
1929	Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. 2002 , 100, 623-6	225
1928	Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. 2002 , 101, 567-75	117
1927	Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. 2002 , 94, 2024-32	58
1926	Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. 2002 , 94, 2996-9	19
1925	Severe periorbital edema secondary to STI571 (Gleevec). 2002 , 95, 881-7	112
1924	Autologous stem cell transplantation for patients with chronic myeloid leukemia. The Argentine Group of Bone Marrow Transplantation (GATMO) experience. 2002 , 95, 2339-45	4
1923	Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. 2002 , 95, 2373-9	159
1922	The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). 2002 , 9, 831-9	114
1921	Imatinib mesylate (Gleevec) in the treatment of 2 patients with Philadelphia-positive ALL relapsing after allogeneic stem cell transplantation. 2002 , 75, 440-2	1
1920	Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis. 2002 , 76, 349-53	4
1919	Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. 2002 , 76, 427-35	17
1918	Treatment of chronic myeloid leukaemia: lessons and challenges. 2002 , 76 Suppl 2, 189-92	7
1917	Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. 2002 , 76 Suppl 2, 193-203	17
1916	The therapy of myelofibrosis: targeting pathogenesis. 2002 , 76 Suppl 2, 296-304	3
1915	Progress in the treatment of acute myeloid leukaemia in adults. 2002 , 76 Suppl 1, 253-8	74

1914	The role of the EBMT activity survey in the management of hematopoietic stem cell transplantation. European Group for Blood Marrow Transplantation. 2002 , 76 Suppl 1, 386-92	12
1913	Older adults with acute myeloid leukemia. 2002 , 4, 403-9	8
1912	Tyrosine kinase inhibitors: a clinical perspective. 2002 , 4, 9-19	36
1911	[Current pharmacotherapy of chronic myeloid leukemia]. 2002 , 43, 270-83	0
1910	[Modern techniques in leukemia diagnosis]. 2002 , 43, 1190, 1193-6, 1199-202	10
1909	[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group]. 2002 , 43, 1228, 1231-8, 1241-4	2
1908	Targeted chemotherapy: chronic myelogenous leukemia as a model. 2002 , 80, 219-32	5
1907	Double-strand breaks and translocations in cancer. 2002 , 59, 373-85	126
1906	Paradigmenwechsel in der Therapie gastrointestinaler Stromatumoren. 2002 , 8, 378-383	1
1905	Diagnostik und Therapie der chronischen myeloischen Leukämie. 2002 , 8, 693-707	
1904	High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. 2002 , 768, 325-40	126
1903	Manifestations rhumatologiques des anticancéreux. 2002 , 69, 424-433	1
1902	Sentinel Lymph Node Biopsy (2001). Ed. Hiram Cody. 2002 , 147, 408-408	
1901	The Principles and Practice of Contact and Occupational Dermatology in the Asia-Pacific Region (2002). Ng See Ket and Gob Chee Leok. 2002 , 147, 408-408	
1900	Loeffler's syndrome and cutaneous larva migrans: a rare association. 2002 , 147, 386-8	27
1899	News and Notices. 2002 , 147, 409-410	
1898	Chronic onycholysis dramatically responds to enhanced intake of carotene-rich food. 2002 , 147, 389-91	6
1897	Straight hair associated with interferon-alfa plus ribavirin in hepatitis C infection. 2002 , 147, 392-3	32

1896	Atopic eczema and the home environment. 2002 , 147, 393; author reply 393-4	
1895	Atopic eczema and the home environment: reply from authors. 2002 , 147, 394-394	
1894	A retrospective analysis of patients with pemphigus vulgaris associated with pregnancy. 2002 , 147, 396-7	15
1893	Sun protection with trees. 2002 , 147, 397-9	15
1892	Topical cidofovir for erythroplasia of Queyrat of the glans penis. 2002 , 147, 399-400	16
1891	Chronic X-ray dermatitis treated by topical 5-aminolaevulinic acid-photodynamic therapy. 2002 , 147, 394-6	9
1890	Multicentric localized giant cell tumour of the tendon sheath: two separate lesions at different sites in a finger. 2002 , 147, 403-5	9
1889	Beta 2 integrin-mediated adherence does not modulate superoxide anion release from neutrophils and subsequent lipid peroxidation of surrounding fibroblasts. 2002 , 147, 401-3	0
1888	The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. 2002 , 147, 405-6	103
1887	Patients' perception of the cause of their melanoma differs from that of epidemiologists. 2002 , 147, 388-9	19
1886	Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders. 2002 , 147, 385-6	47
1885	Nodular localized primary cutaneous amyloidosis. 2002 , 147, 400; author reply 401	4
1884	Nodular localized primary cutaneous amyloidosis: reply from authors. 2002 , 147, 401-401	2
1883	Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. 2002 , 147, 406-7	34
1882	Cellular signalling pathways: new targets in leukaemia therapy. 2002 , 116, 57-77	21
1881	Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. 2002 , 116, 162-5	32
1880	Deletion of sequences flanking the t(9;22) breakpoint: a secondary genetic event associated with loss of cytogenetic response to interferon in a Philadelphia-positive chronic myeloid leukaemia patient. 2002 , 117, 617-9	
1879	Stevens-Johnson syndrome after treatment with STI571: a case report. 2002 , 117, 620-2	76

1878	Low concentrations of STI571 in the cerebrospinal fluid: a case report. 2002 , 117, 623-5	81
1877	Infusion of peripheral blood stem cells collected at diagnosis, with maintenance of the treatment, resulted in Ph-negative recovery in a chronic myeloid leukaemia patient in persisting aplasia on STI-571 therapy. 2002 , 118, 144-6	3
1876	Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. 2002 , 118, 771-7	68
1875	Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. 2002 , 119, 109-11	34
1874	Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. 2002 , 119, 3-14	28
1873	Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. 2002 , 119, 106-8	114
1872	STI-571 in chronic myelogenous leukaemia. 2002 , 119, 15-24	21
1871	Sti571-induced Stevens-Johnson Syndrome. 2002 , 119, 274-5	26
1870	Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab. 2002 , 119, 279-80	18
1869	Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF. 2002 , 119, 275	5
1868	P15INK4B is not mutated in adult familial myelodysplastic syndromes. 2002 , 119, 277-9	3
1867	Congenital afibrinogenaemia in a newborn infant due to a novel mutation in the fibrinogen alpha gene. 2002 , 119, 282-3	11
1866	Serum levels of VEGF do not correlate with the severity of multiple myeloma. 2002 , 119, 276; author reply 276-7	1
1865	Reply to sezer et'al. 2002 , 119, 276-277	
1864	Relapse of severe aplastic anaemia after influenza immunization. 2002 , 119, 283-4	15
1863	Parvovirus b19-associated pure red cell aplasia in chronic graft-versus-host disease. 2002 , 119, 280-1	6
1862	Acquired inhibitor of the intrinsic pathway in a non-haemophilic patient. Control of bleeding by recombinant factor viia. 2002 , 119, 284-5	2
1861	The use of recombinant factor viia in a jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage. 2002 , 119, 286-8	22

1860	BCR-ABL FISH monitoring of CML: a survey of current UK practice. 2002 , 119, 272-3	
1859	Position paper on imatinib mesylate in chronic myeloid leukaemia. 2002 , 119, 268-72	3
1858	Targeting molecular mechanisms in cancer. 2002 , 72, 760-3	1
1857	Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. 2002 , 28, 1183-94	64
1856	Commentary: targeting myelodysplastic syndromes. 2002 , 26, 703	
1855	Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. 2002 , 26, 881-4	104
1854	Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation. 2002 , 30, 453-7	5
1853	Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia. 2002 , 30, 971-3	1
1852	Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. 2002 , 30, 813-31	50
1851	Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. 2002 , 16, 1213-9	90
1850	Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). 2002 , 16, 1220-8	20
1849	Spotlight Imatinib: a model for signal transduction inhibitors. 2002 , 16, 1205-1206	6
1848	Chronic myelogenous leukemia: mechanisms underlying disease progression. 2002 , 16, 1402-11	125
1847	Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. 2002 , 16, 1390-3	100
1846	Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. 2002 , 16, 2027-36	92
1845	Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. 2002 , 16, 1589-95	41
1844	Effects of imatinib on bone marrow engraftment in syngeneic mice. 2002 , 16, 1584-8	21
1843	Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. 2002 , 16, 1579-83	146

1842	Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. 2002 , 16, 2160-1	55
1841	Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia. 2002 , 16, 2159-60	12
1840	Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. 2002 , 16, 2190-6	769
1839	Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. 2002 , 16, 2349-57	77
1838	Dysregulation of apoptosis genes in hematopoietic malignancies. 2002 , 21, 3459-74	134
1837	Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. 2002 , 21, 3847-54	49
1836	Clinical impact of novel treatment strategies. 2002 , 21, 6970-81	39
1835	K252a inhibits the oncogenic properties of Met, the HGF receptor. 2002 , 21, 4885-93	131
1834	Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). 2002 , 21, 5716-24	251
1833	Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. 2002 , 21, 5868-76	136
1832	Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. 2002 , 21, 8075-88	113
1831	Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. 2002 , 21, 8541-6	100
1830	BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. 2002 , 21, 8547-59	88
1829	Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. 2002 , 21, 8584-90	33
1828	BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. 2002 , 21, 8591-604	109
1827	The biology of chronic myelogenous leukemia: mouse models and cell adhesion. 2002 , 21, 8612-28	34
1826	The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma. 2002 , 112, 2114-28	17
1825	Mutations of the BRAF gene in human cancer. 2002 , 417, 949-54	7962

1824	MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. 2002 , 30, 41-7	1525
1823	DNA and its associated processes as targets for cancer therapy. 2002 , 2, 188-200	1091
1822	Emerging immune targets for the therapy of allergic asthma. 2002 , 1, 55-64	38
1821	Protein kinases--the major drug targets of the twenty-first century?. 2002 , 1, 309-15	1691
1820	Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. 2002 , 1, 493-502	1077
1819	Clinical proteomics: translating bedside promise into bedside reality. 2002 , 1, 683-95	439
1818	Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. 2002 , 86, 1487-93	40
1817	The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. 2002 , 86, 1472-8	22
1816	Understanding the action of interferon in hairy cell leukemia: the past as prologue. 2002 , 26, 407-8	
1815	Surgery "ain't" going to cut it. Are we ready?. 2002 , 84, 357-9	0
1814	Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. 2002 , 20, 215-29	46
1813	Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. 2002 , 99, 319-25	969
1812	Childhood leukaemia. 2002 , 324, 283-7	208
1811	Identifying peptide ligands for cell surface receptors using cell-growth-on-bead assay and one-bead one-compound combinatorial library. 2002 , 24, 497-500	27
1810	Signaling inhibitors in the treatment of prostate cancer. 2002 , 20, 159-72	11
1809	Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. 2002 , 100, 1014-8	448
1808	Chronic myelogenous leukemia: elements of conventional chemotherapy and an overview of autografting in the treatment of the chronic phase. 2003 , 20, 95-116	1
1807	Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications. 2003 , 20, 311-24	5

1806	Chemotherapy individualization. 2003 , 21, 149-56	13
1805	Clinical trial design for target specific anticancer agents. 2003 , 21, 243-50	33
1804	Jak family of kinases in cancer. 2003 , 22, 423-34	102
1803	General keynote: molecular therapeutics and pharmacogenomics. 2003 , 88, S84-7; discussion S93-6	2
1802	Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. 2003 , 21, 315-21	33
1801	Chronic myeloid leukemia--advances in biology and new approaches to treatment. <i>New England Journal of Medicine</i> , 2003 , 349, 1451-64	59.2 755
1800	The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution. 2003 , 442, 421-8	39
1799	Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?. 2003 , 77, 93-5	11
1798	The role of the MLL gene in infant leukemia. 2003 , 78, 390-401	34
1797	Clonal analysis of granulocyte-monocyte colony-forming unit cells with the human androgen receptor gene in chronic myeloid leukemia. 2003 , 77, 476-81	1
1796	Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. 2003 , 115, 485-504	22
1795	New drug targeting treatment [Glivec. 2003 , 15, 235-239	
1794	Bcl-2 and apoptosis in chronic lymphocytic leukemia. 2003 , 4, 211-8	51
1793	Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. 2003 , 28, 808-14	53
1792	Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. 2003 , 82, 284-9	72
1791	Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. 2003 , 52, 229-34	9
1790	[Gastrointestinal stromal tumors. A morphologic and molecular genetic independent tumor entity with new therapeutic perspectives]. 2003 , 24, 182-91	7
1789	Zytokine. 2003 , 46, 203-210	

1788	Neue Substanzen und neue Wirkprinzipien in der Onkologie. 2003 , 9, 1058-1087	
1787	Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor. 2003 , 38, 690-4	9
1786	Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. 2003 , 3, 173-83	353
1785	PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR β -induced myeloproliferative disease. 2003 , 3, 459-69	208
1784	Targeting oncogene dependence and resistance. 2003 , 3, 414-7	21
1783	BRAF as a potential therapeutic target in melanoma and other malignancies. 2003 , 4, 95-8	146
1782	Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. 2003 , 70, 235-9	44
1781	Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI). 2003 , 71, 313-4	13
1780	First case of immune-mediated haemolytic anaemia associated to imatinib mesylate. 2003 , 71, 455-8	16
1779	Aggressive systemic mastocytosis. 2003 , 70, 64-6	11
1778	STI571-resistant KT-1 cells are sensitive to interferon-alpha accompanied by the loss of T-cell protein tyrosine phosphatase and prolonged phosphorylation of Stat1. 2003 , 31, 601-8	16
1777	Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. 2003 , 31, 686-92	191
1776	Novel systemic therapies for breast cancer. 2003 , 12, 277-87	7
1775	Gemcitabine and carboplatin regimens in advanced non-small-cell lung cancer: focus on randomized phase III trials. 2003 , 4 Suppl 2, S40-4	9
1774	Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment. 2003 , 3, 21	3
1773	Hematopoietic stem cells in chronic myeloid leukemia. 2003 , 34, 496-506	14
1772	BAALC, a novel marker of human hematopoietic progenitor cells. 2003 , 31, 1051-1056	9
1771	Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. 2003 , 66, 1907-13	56

1770	Targeted molecular therapy for cancer: The application of STI571 to gastrointestinal stromal tumor. 2003 , 40, 131-193	
1769	Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. 2003 , 91, 3-8	55
1768	A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. 2003 , 90, 529-36	61
1767	Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. 2003 , 91, 9-14	80
1766	Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. 2003 , 147, 78-80	14
1765	Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. 2003 , 97, 1033-41	190
1764	Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. 2003 , 97, 2225-8	21
1763	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. 2003 , 97, 2760-6	96
1762	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. 2003 , 97, 3010-6	9
1761	Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. 2003 , 98, 81-5	41
1760	Chronic myelogenous leukemia: a review and update of therapeutic strategies. 2003 , 98, 437-57	61
1759	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. 2003 , 98, 888-93	62
1758	Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. 2003 , 98, 1105-13	74
1757	Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. 2003 , 98, 1430-7	16
1756	Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. 2003 , 98, 2636-42	77
1755	Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. 2003 , 98, 2643-50	31
1754	Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. 2003 , 105, 130-5	57
1753	Gastrointestinal stromal tumors: from a surgical to a molecular approach. 2003 , 107, 171-6	111

1752	Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. 2003 , 40, 276-87	162
1751	Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?. 2003 , 41, 115-7	11
1750	Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571). 2003 , 41, 159-60	1
1749	Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. 2003 , 73, 249-55	11
1748	Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. 2003 , 74, 238-42	30
1747	The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective?. 2003 , 48, 2092-6	76
1746	Cancer therapy: switching off oncogenes. 2003 , 25, 104-7	5
1745	Gastrointestinal stromal tumours. 2003 , 90, 1178-86	245
1744	Identification of novel inhibitors of BCR-ABL tyrosine kinase via virtual screening. 2003 , 13, 3693-9	50
1743	The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. 2003 , 27, 95-120	125
1742	7th International Symposium on Myelodysplastic. 2003 , 27, 1-123	2
1741	Effects of lower dose of imatinib to CML patients. 2003 , 27, 1167	19
1740	Un nouveau traitement pour la leucémie myéloïde chronique : L'imatinib (glivec®) implications pour l'approche diagnostique et le suivi biologique de la maladie. 2003 , 2003, 45-50	
1739	EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. 2003 , 55, 713-23	91
1738	Searching for the gatekeeper oncogene of prostate cancer. 2003 , 46 Suppl, S11-20	5
1737	Mastocytose systémique agressive : ^ propos d'un cas. 2003 , 70, 71-74	
1736	Current views on the pathogenesis of testicular germ cell tumours and perspectives for future research: highlights of the 5th Copenhagen Workshop on Carcinoma in situ and Cancer of the Testis. 2003 , 111, 280-9	39
1735	Mycosis fungoides-like reaction in a patient treated with Gleevec. 2003 , 30, 279-81	33

1734	Mutations of the BRAF gene in benign and malignant melanocytic lesions. 2003 , 121, 1160-2	172
1733	The gist of it: Case reports of a gastrointestinal stromal tumour and a leiomyoma of the anorectum. 2003 , 73, 167-9	13
1732	Hair loss in three patients with acromegaly treated with octreotide. 2003 , 149, 655-6	23
1731	Livedo reticularis induced by amantadine. 2003 , 149, 656-8	25
1730	Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin. 2003 , 149, 656	39
1729	Photosensitivity in Sweet's syndrome: two cases that were photoinduced and photoaggravated. 2003 , 149, 675-7	18
1728	A case of multiple trichoepithelioma with an unusual appearance. 2003 , 149, 674-5	2
1727	A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis. 2003 , 149, 669-72	47
1726	Response of cutaneous Rosai-Dorfman disease to topical and intralesional steroids. 2003 , 149, 672-4	16
1725	Pioglitazone-induced myofibroblast cell death: implications for cutaneous scarring. 2003 , 149, 665-7	5
1724	Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. 2003 , 149, 662-3	52
1723	Oral pyoderma gangrenosum. 2003 , 149, 663-4	18
1722	Eruptive angiomatous lesions associated with graft-versus-host disease. 2003 , 149, 667-8	19
1721	A case of malignant atrophic papulosis successfully treated with nicotine patches. 2003 , 149, 660-2	17
1720	Bupropion and generalized acute urticaria: a further case. 2003 , 149, 660	19
1719	Erythema multiforme-like lesions in syphilis. 2003 , 149, 658-60	16
1718	Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib. 2003 , 149, 678-9	22
1717	Colour Atlas of Dermoscopy, 2nd enlarged and completely revised Edition (2002). 2003 , 149, 680-680	

- 1716 British Society of Paediatric Dermatology 18th Annual Meeting. 14-15 November 2003, Dublin, Ireland. **2003**, 149, 680-680
- 1715 Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. **2003**, 120, 500-4 5
- 1714 Gene polymorphisms associated with diminished activity of 5,10-methylenetetrahydrofolate reductase do not explain the clinical manifestations of cobalamin deficiency. **2003**, 120, 907-9 4
- 1713 Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. **2003**, 120, 909-10 35
- 1712 Ca²⁺ ionophore-induced dendritic cell differentiation in a patient with defective Ca²⁺ ionophore-induced platelet aggregation. **2003**, 120, 910-1
- 1711 A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). **2003**, 120, 911-3 34
- 1710 Plasma protein Z deficiency is common in women with antiphospholipid antibodies. **2003**, 120, 913-4 21
- 1709 Intensive triathlon training induces low peripheral CD34⁺ stem cells. **2003**, 120, 914-5 5
- 1708 Factor VIII assays in haemophilia a patients treated with ReFacto. **2003**, 121, 379-80 8
- 1707 Pseudoautosomal linkage of familial Hodgkin's lymphoma: molecular analysis of a unique family with Leri-Weill dyschondrosteosis and Hodgkins lymphoma. **2003**, 121, 377-9 5
- 1706 Precipitation of porphyria cutanea tarda by imatinib mesylate?. **2003**, 121, 375 15
- 1705 Recovery of cells with a normal karyotype in a refractory anaemia patient with monosomy 7-positive cells after long-term administration of cyclosporin A. **2003**, 121, 376-7 1
- 1704 Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration. **2003**, 121, 469-72 17
- 1703 Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate. **2003**, 123, 366-7 2
- 1702 Apoptosis and leukaemia. **2003**, 123, 577-85 11
- 1701 Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. **2003**, 25, 119-25 7
- 1700 Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571. **2003**, 25, 293-6 3
- 1699 Management of Molecular-Targeted Therapy for Chronic Myelogenous Leukemia. **2003**, 15, 340-344

1698 Erratum for May 2003 issue. **2003**, 15, 346-346

1697 Management of molecular-targeted therapy for chronic myelogenous leukemia. **2003**, 15, 292-6 7

1696 Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors. **2003**, 94, 315-20 84

1695 Dose-dependent severe cutaneous reactions to imatinib. **2003**, 88, 1157-9 26

1694 Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. **2003**, 89, 634-40 26

1693 Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. **2003**, 31, 611-4 5

1692 Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia. **2003**, 31, 1119-25 13

1691 Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Soci  Fran aise de Greffe de Moelle et de Th rapie Cellulaire (SFGM-TC). **2003**, 32, 993-9 24

1690 Inducible p27(Kip1) expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors. **2003**, 10, 290-301 25

1689 Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. **2003**, 17, 290-7 72

1688 Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. **2003**, 17, 461-3 71

1687 Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. **2003**, 17, 463-5 18

1686 Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. **2003**, 17, 481-7 106

1685 A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. **2003**, 17, 554-9 8

1684 Induction and postremission therapy: new agents. **2003**, 17, 496-8 1

1683 Intramuscular edema as a complication of treatment with imatinib. **2003**, 17, 804-5 17

1682 Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). **2003**, 17, 691-9 31

1681 Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. **2003**, 17, 829-38 93

1680	Histological features of acute hepatitis after imatinib mesylate treatment. 2003 , 17, 978-9	42
1679	Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. 2003 , 17, 1211-62	83
1678	In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. 2003 , 17, 999-1009	35
1677	Stem cells and diversity. 2003 , 17, 1042-8	12
1676	Current CML therapy: progress and dilemma. 2003 , 17, 1010-2	23
1675	Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia. 2003 , 17, 1414-6	9
1674	Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. 2003 , 17, 1448-53	60
1673	Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. 2003 , 17, 1454-63	130
1672	A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. 2003 , 17, 1794-805	140
1671	Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. 2003 , 17, 1707-12	89
1670	Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. 2003 , 17, 1713-21	51
1669	Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. 2003 , 22, 660-4	159
1668	Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c. 2003 , 22, 4074-82	30
1667	Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. 2003 , 22, 5338-47	180
1666	Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. 2003 , 22, 7389-95	194
1665	Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. 2003 , 22, 7414-30	228
1664	Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. 2003 , 22, 8441-7	50
1663	Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. 2003 , 16, 366-75	89

1662	Kit expression in small cell carcinomas of the lung: effects of chemotherapy. 2003 , 16, 1041-7	46
1661	A small molecule Abl kinase inhibitor induces differentiation of Abelson virus-transformed pre-B cell lines. 2003 , 4, 31-7	137
1660	Cancer revoked: oncogenes as therapeutic targets. 2003 , 3, 375-80	342
1659	The genetics of malignant melanoma: lessons from mouse and man. 2003 , 3, 559-70	216
1658	New models to investigate mechanisms of disease genesis from primitive BCR-ABL(+) hematopoietic cells. 2003 , 996, 1-9	5
1657	Dendritic cell vaccination for patients with chronic myelogenous leukemia. 2003 , 27, 795-802	41
1656	Farnesyl transferase inhibitors in myeloid malignancies. 2003 , 17, 123-9	20
1655	Ocular adverse drug reactions. 2003 , 2, 411-20	11
1654	Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. 2003 , 5, 96-102	147
1653	Polycythemia vera: a comprehensive review and clinical recommendations. 2003 , 78, 174-94	118
1652	Experimental approaches to treatment of soft tissue sarcoma. 2003 , 12, 499-521	4
1651	Chronic myeloid leukemia. 2003 , 17, 1159-73, vi-vii	10
1650	Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes. 2003 , 17, 1243-60	3
1649	Clinical trials and soft tissue sarcomas. 2003 , 12, 485-97	8
1648	Myeloproliferative and myelodysplastic syndromes: the future. 2003 , 17, 1261-9	2
1647	Primer on medical genomics. Part VI: Genomics and molecular genetics in clinical practice. 2003 , 78, 307-17	20
1646	Receptor induction and targeted drug delivery: a new antileukaemia strategy. 2003 , 3, 563-74	28
1645	Tyrosine kinases as targets in cancer therapy - successes and failures. 2003 , 7, 215-34	171

1644	Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. 2003 , 125, 660-7		571
1643	Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. 2003 , 2, 1		211
1642	Effects of STI571 (gleevec) on pancreatic cancer cell growth. 2003 , 2, 32		37
1641	Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. 2003 , 63, 513-22; discussion 523-4		83
1640	Quality of life on imatinib. 2003 , 40, 31-6		8
1639	Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2003 , 349, 1423-32	59.2	996
1638	Chapter 20. Beyond kinases: Purine-binding enzymes as cancer targets. 2003 , 38, 193-202		4
1637	Specific targeted therapy of chronic myelogenous leukemia with imatinib. 2003 , 55, 401-23		257
1636	Translation of basic research into useful treatments: how often does it occur?. 2003 , 114, 503-5		39
1635	Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. 2003 , 162, 521-31		286
1634	Genetic and biological subgroups of low-stage follicular thyroid cancer. 2003 , 162, 1053-60		129
1633	Targeted therapies for the treatment of cancer. 2003 , 186, 264-8		59
1632	Hereditary colorectal cancer. <i>New England Journal of Medicine</i> , 2003 , 348, 919-32	59.2	1540
1631	STI-571: an anticancer protein-tyrosine kinase inhibitor. 2003 , 309, 709-17		83
1630	Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. 2003 , 17, 2401-9		133
1629	Targeted therapy in non-small cell lung cancer: myth or reality. 2003 , 41 Suppl 1, S3-8		29
1628	Imatinib in small cell lung cancer. 2003 , 41 Suppl 1, S49-53		48
1627	Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard?. 2003 , 361, 1400-1		7

1626	Using "rationally designed drugs" rationally. 2003 , 361, 1758-9	6
1625	The 2003 NRPB report on UK nuclear-test veterans. 2003 , 361, 1759-60	3
1624	Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. 2003 , 362, 617-9	29
1623	MLL-rearranged leukemias: insights from gene expression profiling. 2003 , 40, 268-73	56
1622	Prognostic factors in chronic myeloid leukemia: Allografting. 2003 , 40, 13-21	3
1621	Management of chronic myeloid leukemia: Targets for molecular therapy. 2003 , 40, 34-49	12
1620	Imatinib alone and in combination for chronic myeloid leukemia. 2003 , 40, 50-58	65
1619	Advanced-phase chronic myeloid leukemia. 2003 , 40, 79-86	37
1618	Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. 2003 , 40, 87-96	17
1617	Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line. 2003 , 199, 61-8	23
1616	An overview of targeted treatments in cancer. 2003 , 25, 2121-37	75
1615	Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. 2003 , 29, 31-44	37
1614	Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase. 2003 , 40, 10-7	5
1613	Chronic myeloid leukemia in the imatinib era. 2003 , 40, 1-3	14
1612	Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors. 2003 , 40, 11-4	20
1611	Imatinib: a targeted clinical drug development. 2003 , 40, 15-20	19
1610	Imatinib treatment: specific issues related to safety, fertility, and pregnancy. 2003 , 40, 21-5	139
1609	Prediction of response to imatinib by cDNA microarray analysis. 2003 , 40, 42-9	23

1608	The cytogenetic response as a surrogate marker of survival. 2003 , 40, 56-61	17
1607	Cytogenetic studies in patients on imatinib. 2003 , 40, 50-5	69
1606	Molecular monitoring of chronic myeloid leukemia. 2003 , 40, 62-8	73
1605	Cytogenetic and molecular mechanisms of resistance to imatinib. 2003 , 40, 69-79	48
1604	Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. 2003 , 40, 80-2	67
1603	Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials. 2003 , 40, 92-7	11
1602	Clinical decisions for chronic myeloid leukemia in the imatinib era. 2003 , 40, 98-103; discussion 104-13	24
1601	Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. 2003 , 40, 26-30	45
1600	Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. 2003 , 48, 201-6	173
1599	Diagnosis, treatment, and nursing care of patients with chronic leukemia. 2003 , 19, 109-17	5
1598	Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. 2003 , 4, 75-85	308
1597	Molecular biology in diagnostic histopathology. Part 3: signal transduction. 2003 , 9, 397-407	1
1596	Gleevec inhibits beta-amyloid production but not Notch cleavage. 2003 , 100, 12444-9	159
1595	A guide to clinically relevant drug interactions in oncology. 2003 , 9, 45-85	27
1594	Diagnostic application of FISH to hematological malignancies. 2003 , 21, 807-14	7
1593	Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. 2003 , 44, 1239-41	55
1592	Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. 2003 , 101, 4701-7	447
1591	Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. 2003 , 138, 819-30	223

1590	Imatinib Mesylate. 2003 , 2, 439-454	5
1589	Chronic Myeloid Leukemia. 2003 , 2, 305-311	1
1588	Antisense Therapy. 2003 , 2, 245-252	
1587	High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia. 2003 , 44, 411-27	20
1586	Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?. 2003 , 3, 127-9	
1585	Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment, and clinical implications. 2003 , 44, 1089-104	22
1584	New Antileukemic Agents. 2003 , 20, 173-185	1
1583	Ethical hurdles for translational research. 2003 , 160, 1-4	14
1582	Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors. 2003 , 3, 757-66	11
1581	MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. 2003 , 101, 2368-73	453
1580	Ocular side-effects associated with imatinib mesylate (Gleevec). 2003 , 19, 371-5	79
1579	Cancer target discovery using SAGE. 2003 , 7, 759-69	7
1578	Purine nucleoside analogues in the treatment of myeloid leukemias. 2003 , 44, 391-409	64
1577	Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. 2003 , 35, 362-7	78
1576	Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy. 2003 , 21, 553-63	15
1575	Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. 2003 , 101, 4714-6	132
1574	ERRATUM. 2003 , 21, 3890-3890	
1573	BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. 2003 , 101, 690-8	574

1572	Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2003 , 348, 1048-50	59.2	149
1571	Interaction of imatinib mesilate with human P-glycoprotein. 2003 , 307, 824-8		137
1570	In Reply:. 2003 , 21, 3887-3888		0
1569	Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. 2003 , 21, 740-53		51
1568	Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 2003 , 88, 1897-902		106
1567	Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis. 2003 , 21, 3171-3		34
1566	Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. 2003 , 304, 1085-92		226
1565	Challenging problems in advanced malignancy: Case 4. Use of positron emission tomography to solve a diagnostic dilemma in a patient with non-Hodgkin's lymphoma. 2003 , 21, 3173-6		
1564	Activation of tyrosine kinases in cancer. 2003 , 8, 531-8		152
1563	Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia. 2003 , 21, 172-3		10
1562	Challenging problems in advanced malignancy: Case 2. Disseminated intravascular coagulation in metastatic hormone-refractory prostate cancer. 2003 , 21, 3170-1		7
1561	Chemoradiotherapy in unresectable squamous cell head and neck cancer. 2003 , 21, 3887; author reply 3887-8		
1560	Long-term survivors of testicular cancer. 2003 , 21, 3888; author reply 3888-9		
1559	Opportunities and challenges in the development of kinase inhibitor therapy for cancer. 2003 , 17, 2998-3010		130
1558	Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). 2003 , 278, 32892-8		51
1557	Ovarian sex cord-stromal tumors in children and adolescents. 2003 , 21, 2357-63		95
1556	Cancer genetics or cancer genomics in the era of genomic medicine?. 2003 , 14 Suppl 3, iii19-25		3
1555	Rational approaches to human cancer immunotherapy. 2003 , 73, 3-29		93

1554	A 41-year-old woman with chronic myelogenous leukemia. 2003 , 290, 1083-90	
1553	Ethics of phase 1 oncology studies: reexamining the arguments and data. 2003 , 290, 1075-82	145
1552	Imatinib mesylate in the treatment of chronic myeloid leukaemia. 2003 , 4, 963-71	40
1551	Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. 2003 , 102, 4512-9	60
1550	The role of growth factors for disease and therapy in diseases of the head and neck. 2003 , 22, 593-606	5
1549	Current therapies in ovarian cancer. 2003 , 21, 148-56	23
1548	Is there a cloud in the silver lining for imatinib?. 2003 , 88, 983-7	24
1547	Multiple primary cancer, including transitional cell carcinoma of the upper uroepithelial tract in a multigeneration HNPCC family: molecular genetic, diagnostic, and management implications. 2003 , 98, 664-70	14
1546	Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. 2003 , 89, 1855-9	124
1545	Farnesyl transferase inhibitors in the treatment of breast cancer. 2003 , 12, 413-21	26
1544	Coagulopathy, marantic endocarditis, and cerebrovascular accidents as paraneoplastic features in medullary thyroid cancer--case report and review of the literature. 2003 , 13, 601-5	21
1543	Novel FLT3 tyrosine kinase inhibitors. 2003 , 12, 1951-62	26
1542	Practical management of patients with chronic myeloid leukemia receiving imatinib. 2003 , 21, 1637-47	325
1541	Challenging problems in advanced malignancy: Case 1. Chylopericardium during the treatment of non-Hodgkin's lymphoma. 2003 , 21, 3168-70	3
1540	Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy. 2003 , 14, 2695-702	15
1539	It's the poison that killed him, you say!. 2003 , 21, 3885	1
1538	In Reply:. 2003 , 21, 3888-3889	
1537	Tumor Suppressor Genes. 2003 ,	1

1536	A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. <i>New England Journal of Medicine</i> , 2003 , 348, 1201-14	59.2	1426
1535	Signal transduction--directed cancer treatments. 2003 , 43, 199-231		76
1534	Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. 2003 , 21, 4342-9		1885
1533	Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2003 , 348, 994-1004	59.2	2797
1532	Deletion of the 5'ABL region in Philadelphia chromosome positive chronic myeloid leukemia: frequency, origin and prognosis. 2003 , 44, 1333-8		14
1531	STI571 as a targeted therapy for CML. 2003 , 21, 429-38		54
1530	Tyrosine kinase inhibitors as cancer therapy. 2003 , 21, 758-71		11
1529	IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. 2003 , 100, 11630-5		14
1528	A review of imatinib mesilate in the treatment of patients with gastrointestinal stromal tumours and chronic myeloid leukaemia. 2003 , 9, 1-14		
1527	Handbook of Proteomic Methods. 2003 ,		
1526	Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. 2003 , 100, 7830-5		183
1525	Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. 2003 , 278, 23630-8		47
1524	Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?. 2003 , 95, 1813-5		7
1523	In Reply:. 2003 , 21, 3886-3887		3
1522	c-kit proto-oncogene product is rarely detected in colorectal adenocarcinoma. 2003 , 21, 3885-6; discussion 3886-7		15
1521	The importance of paternal family history in hereditary breast cancer is underappreciated by health care professionals. 2003 , 64, 220-6		23
1520	Validating immunohistochemical staining for KIT (CD117). 2003 , 119, 325-7		35
1519	Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. 2003 , 2, 544-51		65

1518	Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes. 2003 , 2, 103-8	13
1517	Identification of signature genes by microarray for acute myeloid leukemia without maturation and acute promyelocytic leukemia with t(15;17)(q22;q12)(PML/RAR α). 2003 , 23, 617	1
1516	Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. 2003 , 23, 681	1
1515	Interstitial cells in the musculature of the gastrointestinal tract: Cajal and beyond. 2003 , 229, 115-208	79
1514	Receptor tyrosine kinases: the main targets for new anticancer therapy. 2003 , 4, 113-21	75
1513	Characterization of translocations in human cancer. 2003 , 222, 327-37	
1512	Consent forms for oncology trials. <i>New England Journal of Medicine</i> , 2003 , 348, 1496-7; author reply 1496-7	5
1511	Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign. 2003 , 207, 329-30	17
1510	Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. 2003 , 88, 5043-4; author reply 5044	4
1509	What is bone mineralization?. 2003 , 88, 5043	3
1508	Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. 2003 , 76, 455-8; discussion 471-3	35
1507	Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571). 2003 , 14, 651-7	10
1506	Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance. 2003 , 25, 507-8	6
1505	Hematopoietic transplantation from adult unrelated donors. 2003 , 8, 99-108	1
1504	The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining. 2003 , 11, 56-61	18
1503	C-kit expression in uterine leiomyosarcomas: an immunocytochemical study of 29 cases of malignant smooth muscle tumors of the uterus. 2003 , 15, 81-4	7
1502	C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance. 2003 , 22, 149-55	25
1501	BAALC, a novel marker of human hematopoietic progenitor cells*1. 2003 , 31, 1051-1056	50

1500	Interferons: mechanisms of action and clinical applications. 2003 , 15, 431-9	145
1499	Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?. 2003 , 14, 751-60	7
1498	Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. 2003 , 25, 644-8	20
1497	Bone marrow biopsy: interpretive guidelines for the surgical pathologist. 2003 , 10, 8-26	26
1496	Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update. 2003 , 10, 40-8	8
1495	The drug development process: from target discovery to the clinic. 2003 , 3, 323-6	2
1494	. 2003 , 11, 56-61	9
1493	Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. 2003 , 75, 334-9	18
1492	Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. 2003 , 75, 1147-53	48
1491	Molecular cancer therapeutics: recent progress and targets in drug resistance. 2003 , 42, 237-43	36
1490	[Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy]. 2003 , 121, 119-28	1
1489	Src family kinases: potential targets for the treatment of human cancer and leukemia. 2003 , 9, 2043-59	105
1488	The future of GI and liver research: editorial perspectives. III. JNK/AP-1 regulation of hepatocyte death. 2003 , 284, G875-9	97
1487	Chronic Myeloid Leukaemia. 2003 ,	
1486	Inhibiting Signaling Pathways through Rational Drug Design. 447-457	
1485	The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. 2003 , 101, 655-63	42
1484	Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. 2003 , 101, 664-72	125
1483	Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. 2003 , 101, 441-5	185

1482	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. 2003 , 101, 473-5	273
1481	TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. 2003 , 101, 3658-67	76
1480	A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. 2003 , 101, 3188-97	98
1479	Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. 2003 , 101, 3794-800	183
1478	Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. 2003 , 102, 276-83	635
1477	The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. 2003 , 101, 5010-3	86
1476	Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. 2003 , 101, 3391-7	187
1475	Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. 2003 , 101, 4088-97	29
1474	Stem cell transplantation for chronic myeloid leukemia in children. 2003 , 102, 1224-31	83
1473	B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs. 2003 , 102, 3317-22	38
1472	Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. 2003 , 101, 4611-4	280
1471	Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). 2003 , 102, 2236-9	139
1470	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. 2003 , 102, 83-6	164
1469	Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. 2003 , 102, 2220-8	44
1468	Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. 2003 , 102, 4499-503	77
1467	The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. 2003 , 102, 2229-35	117
1466	Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. 2003 , 102, 3880-9	72
1465	Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. 2003 , 102, 2240-2	35

1464	The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. 2003 , 102, 3765-74	245
1463	Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. 2003 , 102, 3786-92	17
1462	Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. 2003 , 102, 4298-305	55
1461	PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. 2003 , 102, 4354-60	38
1460	CHIC2 deletion, a surrogate for FIP1L1-PDGFR α fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. 2003 , 102, 3093-6	327
1459	Chromosomal abnormalities in Ph- cells of patients on imatinib. 2003 , 102, 2700-1; author reply 2701	21
1458	Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. 2003 , 102, 2702-3; author reply 2703-4	73
1457	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. 2003 , 101, 97-100	128
1456	Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. 2003 , 101, 446-53	61
1455	HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. 2003 , 102, 31-5	150
1454	Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. 2003 , 102, 1933-4; author reply 1934-5	13
1453	Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor. 2003 , 122, 482-90	4
1452	Cancer genetics in primary care. 2003 , 133, 3767S-3772S	6
1451	Fluorescence in-situ Hybridization (FISH) A Rapid and Useful Technique for Diagnosis and Management in Leukemia. 2003 , 3, 115-119	2
1450	Imatinib: A targeted clinical drug development. 2003 , 40, 15-20	17
1449	Integration of Pharmacogenomics into Medical Practice. 135-161	2
1448	Cytogenetic and molecular mechanisms of resistance to imatinib. 2003 , 40, 69-79	45
1447	. 2003 ,	19

1446	. 2003 ,	24
1445	. 2003 ,	9
1444	Authors[Response: Effect of Imatinib Mesylate (Gleevec) on Anaplastic Thyroid Carcinoma Cell Lines. 2003 , 88, 5044-5044	
1443	[Oncology 2003: new therapeutic perspectives]. 2003 , 19, 131	0
1442	The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro. 2003 , 44, 1549-55	10
1441	[Oncogenes and leukemia: history and perspectives]. 2003 , 19, 201-10	1
1440	Clinical applications of proteomics. 2003 , 133, 2476S-2484S	65
1439	How to monitor patients with chronic myelogenous leukemia. 2003 , 1, 513-7	
1438	Uncommon syndromes and treatment manifestations of malignancy: Case 3. Richter's syndrome heralded by refractory hypercalcemia. 2003 , 21, 170-2	6
1437	Uncommon syndromes and treatment manifestations of malignancy: Case 1. Unusual association of lupus and sarcoma. 2003 , 21, 166-7	3
1436	Uncommon syndromes and treatment manifestations of malignancy: Case 2. Metastatic non-small-cell lung cancer presenting with leukocytosis. 2003 , 21, 168-70	49
1435	Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. 2003 , 109, 119-23	3
1434	Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate. 2003 , 83, 391-2	8
1433	[Gastric MALT lymphoma and gastrointestinal stromal tumors (GIST)]. 2004 , 93, 2143-50	1
1432	Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses. 2004 , 140, 584-8	9
1431	[Predicting response to Iressa: unexpected mechanism]. 2004 , 20, 750-1	0
1430	Chronic myeloid leukemia and the application of rational drug design. 2004 , 6, 497	
1429	Pharmacodynamic Assays in Cancer Drug Discovery: From Preclinical Validation to Clinical Trial Monitoring. 2004 , 227-254	

1428	KIT and PDGF as targets. 2004 , 120, 117-27	2
1427	Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas. 2004 , 120, 129-50	4
1426	Clinical Development Issues. 2004 , 287-306	1
1425	Cancer Genetics and Drug Target Selection. 2004 , 41-53	
1424	Kinase inhibitors in leukemia. 2004 , 51, 1-33	
1423	Molecular biological design of novel antineoplastic therapies. 2004 , 13, 577-607	4
1422	Clinical and epidemiologic burden of chronic myelogenous leukemia. 2004 , 4, 85-96	31
1421	Endocrine therapy and other targeted therapies for metastatic breast cancer. 2004 , 4, 1179-95	7
1420	Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. 2004 , 4, 285-99	139
1419	Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects. 2004 , 4, 255-71	11
1418	Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation. 2004 , 4, 403-24	19
1417	Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy—a fluorescence in-situ hybridization study. 2004 , 45, 1627-31	6
1416	The molecular basis of leukemia. 2004 , 2004, 80-97	180
1415	Detection of trisomy 8 in donor-derived Ph ⁻ cells in a patient with Ph ⁺ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation. 2004 , 45, 1453-8	6
1414	Inhibitors of cellular signaling targets: designs and limitations. 2004 , 273, 87-102	2
1413	Small molecule FLT3 tyrosine kinase inhibitors. 2004 , 10, 1183-93	26
1412	A new paradigm in the treatment of carcinoma: specific molecular targeting. 2004 , 145, 1027-30	3
1411	Development and possible clinical use of antagonists for PDGF and TGF-beta. 2004 , 109, 165-78	17

1410	Protein tyrosine kinase inhibitors as anticancer agents. 2004 , 14, 35-53	29
1409	Principles of Molecular Oncology. 2004 ,	6
1408	Overriding imatinib resistance with a novel ABL kinase inhibitor. 2004 , 305, 399-401	1514
1407	Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). 2004 , 10, 2265-71	18
1406	c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. 2004 , 15, 594-7	41
1405	Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. 2004 , 10, 8351-6	58
1404	Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. 2004 , 64, 6385-9	158
1403	Utilization of microarrayed compound screening (microARCS) to identify inhibitors of p56lck tyrosine kinase. 2004 , 9, 12-21	7
1402	Subdural hematomas during CML therapy with imatinib mesylate. 2004 , 45, 1633-6	30
1401	Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. 2004 , 10, 5732-40	89
1400	Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. 2004 , 10, 155-65	73
1399	The role of signal transducer and activator of transcription factors in leukemogenesis. 2004 , 22, 361-71	56
1398	Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. 2004 , 10, 68-75	49
1397	Targeting Treatment of Soft Tissue Sarcomas. 2004 ,	
1396	Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. 2004 , 10, 5065-71	65
1395	Gleevec: prototype or outlier?. 2004 , 2004, pe12	14
1394	Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. 2004 , 24, 2573-83	62
1393	Indications for imatinib mesylate therapy and clinical management. 2004 , 9, 271-81	149

1392	Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. 2004 , 96, 46-55	138
1391	Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs. 2004 , 10, 3980-7	36
1390	Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. 2004 , 10, 681-90	101
1389	Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance. 2004 , 112, 85-92	6
1388	t(8;21)(q22;q22) in Blast Phase of Chronic Myelogenous Leukemia. 2004 , 121, 836-842	45
1387	Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells. 2004 , 279, 32813-23	48
1386	The significance of KIT (CD117) in gastrointestinal stromal tumors. 2004 , 12, 93-7	15
1385	Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. 2004 , 64, 5322-31	66
1384	Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. 2004 , 104, 2655-60	180
1383	Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST). 2004 , 3, 251-8	37
1382	Surrogate markers in oncology practice and anticancer drug development: lessons learned from antiretroviral therapy?. 2004 , 22, 164-8	
1381	Gastrointestinal stromal tumors--a review. 2004 , 75, 62-71	45
1380	Imatinib attenuates diabetes-associated atherosclerosis. 2004 , 24, 935-42	116
1379	Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor. 2004 , 5, 386-90	14
1378	Novel therapies for patients with chronic myeloid leukemia. 2004 , 4, 271-82	2
1377	Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. 2004 , 3, 385-92	47
1376	Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. 2004 , 3, 1502-5	90
1375	Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. 2004 , 10, 3885-96	142

1374	Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. 2004 , 22, 4816-22	41
1373	Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. 2004 , 10, 6661-8	200
1372	Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. 2004 , 10, 2525-9	59
1371	Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. 2004 , 22, 4442-5	200
1370	Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. 2004 , 279, 25345-52	57
1369	Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. 2004 , 64, 3780-9	117
1368	The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. 2004 , 91, 1174-80	45
1367	New chondrocyte genes discovered by representational difference analysis of chondroinduced human fibroblasts. 2004 , 176, 41-53	21
1366	Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. 2004 , 64, 2333-7	280
1365	Imatinib-induced pulmonary oedema. 2004 , 15, 57-59	
1364	Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. 2004 , 45, 237-45	13
1363	Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. 2004 , 45, 2349-51	33
1362	Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. 2004 , 10, 751-61	72
1361	Response of oral lichen planus to topical tacrolimus in 37 patients. 2004 , 140, 1508-12	59
1360	Systemic therapy of soft tissue sarcoma: an improvement in outcome. 2004 , 15 Suppl 4, iv193-6	7
1359	Optimizing treatment of chronic myeloid leukemia: a rational approach. 2004 , 9, 259-70	34
1358	Targeting the platelet-derived growth factor receptor in antivasular therapy for human ovarian carcinoma. 2004 , 10, 897-908	84
1357	Growth factor receptor expression in orbital lymphangioma: possible therapeutic implications. 2004 , 23, 263-9	8

1356	Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. 2004 ,	7
1355	Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. 2004 , 5, 168-77	13
1354	Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies. 2004 , 58, 511-6	40
1353	What are the reasons for negative phase III trials of molecular-target-based drugs?. 2004 , 95, 772-6	12
1352	p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. 2004 , 95, 186-92	37
1351	Follicular mucinosis associated with imatinib (STI571). 2004 , 151, 1276-8	22
1350	Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. 2004 , 125, 500-11	22
1349	Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib. 2004 , 34, 243-4	5
1348	Kinase inhibitors in cancer therapy. 2004 , 2, 177-93	22
1347	Combined use of fasting glucose and hemoglobin a levels in screening for new type 2 diabetes mellitus in elderly men: TCVGHAGE. 2004 , 52, 1777-8	2
1346	Theophylline-improved swallowing reflex in elderly nursing home patients. 2004 , 52, 1787-8	13
1345	Response Letter to Dr. Raschilas et al.. 2004 , 52, 1789-1789	
1344	Type 2 diabetes mellitus as a risk factor for hip fracture. 2004 , 52, 1778-9	13
1343	A case of cutaneous horn in a 99-year-old woman. 2004 , 52, 1779-80	
1342	A clinicopathological study of rest tremors in the elderly. 2004 , 52, 1781-3	4
1341	An 85-year-old Japanese woman with Philadelphia chromosome-positive chronic myelogenous leukemia with del (5q) successfully treated by intermittent imatinib therapy. 2004 , 52, 1783-4	
1340	Buformin-induced lactic acidosis--a symptom of modern healthcare malady. 2004 , 52, 1785	7
1339	Retroperitoneal abscess after sphincterotomY-related perforation. 2004 , 52, 1786	

1338	Gustatory rhinorrhea as a complication of oral surgery. 2004 , 52, 1786-7	4
1337	Imatinib mesylate in cutaneous melanoma. 2004 , 123, 1208-9	17
1336	Imatinib mesylate for melanoma: will a new target be revealed?. 2004 , 123, xi-xiii	7
1335	Controlling Abl: auto-inhibition and co-inhibition?. 2004 , 6, 3-7	57
1334	Treating cancer's kinase 'addiction'. 2004 , 10, 786-7	52
1333	Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. 2004 , 10, 1187-9	199
1332	Switching on kinases: oncogenic activation of BRAF and the PDGFR family. 2004 , 4, 718-27	142
1331	Development of novel targeted therapies in the treatment of malignant glioma. 2004 , 3, 430-46	187
1330	Regulation of the c-Abl and Bcr-Abl tyrosine kinases. 2004 , 5, 33-44	380
1329	Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. 2004 , 33, 53-60	33
1328	Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment. 2004 , 33, 237-42	10
1327	Do cells need CDK2 and ... Bcr-Abl?. 2004 , 11, 249-51	23
1326	Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). 2004 , 18, 760-2	44
1325	Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. 2004 , 18, 182	15
1324	CLL B cells with a bimodal CD38 expression pattern: persistence of bimodal populations despite effective therapy for B-CLL. 2004 , 18, 180-2	5
1323	P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. 2004 , 18, 401-8	269
1322	TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways. 2004 , 18, 548-55	39
1321	Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis. 2004 , 18, 1027-9	18

1320	Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL. 2004 , 18, 1006-12	13
1319	Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. 2004 , 18, 1332-9	111
1318	Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. 2004 , 18, 1321-31	276
1317	Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts. 2004 , 18, 1539-40	22
1316	Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. 2004 , 23, 6056-63	203
1315	Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. 2004 , 90, 1825-9	40
1314	DNA sequence and analysis of human chromosome 9. 2004 , 429, 369-74	102
1313	Ertapanem therapy for community-acquired pneumonia in the elderly. 2004 , 52, 1788-9; author reply 1789	
1312	Do older people tolerate ambulatory blood pressure monitoring?. 2004 , 52, 1780-1	3
1311	Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. 2004 , 14, 23-31	7
1310	Targeted therapies in myeloid leukemia. 2004 , 14, 41-62	39
1309	Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. 2004 , 14, 307-15	15
1308	Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. 2004 , 5, 91-102	597
1307	BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. 2004 , 5, 275-85	102
1306	[New pharmacological strategies for the treatment of cancer]. 2004 , 28, 167-80	1
1305	[Clinical management of gastrointestinal stromal tumors]. 2004 , 28, 893-901	5
1304	Role of KIT and platelet-derived growth factor receptors as oncoproteins. 2004 , 31, 4-11	61
1303	Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. 2004 , 31, 24-9	27

1302	Monitor. 2004 , 9, 43-44	3
1301	A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate. 2004 , 148, 152-4	5
1300	Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans. 2004 , 24, 1232-5	11
1299	The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. 2004 , 24, 1508-14	88
1298	Cyclooxygenase-2 inhibitors in lung cancer. 2004 , 5, 245-53	5
1297	Smart drugs in prostate cancer. 2004 , 45, 1-17	27
1296	Molecular mechanisms of prostate cancer. 2004 , 45, 683-91	56
1295	Chronic myeloid leukemia-still a few questions. 2004 , 32, 2-10	36
1294	Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. 2004 , 32, 375-81	72
1293	A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein. 2004 , 32, 1057-63	30
1292	Establishment and characterization of an STI571-resistant human myelogenous leukemia cell line, SR-1. 2004 , 154, 52-6	2
1291	Challenging pedigrees seen in a hereditary cancer consultation center. 2004 , 153, 91-101	2
1290	Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. 2004 , 5, 525-31	82
1289	Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. 2004 , 6, 577-86	152
1288	Somatic alterations in the human cancer genome. 2004 , 6, 433-8	128
1287	Multicenter prospective study of interferon alpha versus allogeneic stem cell transplantation for patients with new diagnoses of chronic myelogenous leukemia. 2004 , 79, 345-53	4
1286	Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. 2004 , 79, 420-33	35
1285	Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. 2004 , 79, 441-7	12

1284	Imatinib mesylate in the treatment of chronic myelogenous leukemia. 2004 , 79, 411-9		12
1283	Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. 2004 , 80, 261-6		17
1282	Selective effect of imatinib on serum IgM in a patient with CML. 2004 , 80, 381-2		2
1281	Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it. 2004 , 258, 25-33		18
1280	Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. <i>New England Journal of Medicine</i> , 2004 , 350, 2129-39	59.2	9266
1279	Apoptosis induced by molecular targeting therapy in hematological malignancies. 2004 , 111, 107-23		15
1278	A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients. 2004 , 39, 329-33		7
1277	Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia. 2004 , 130, 59-72		19
1276	Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells. 2004 , 130, 711-8		4
1275	Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. 2004 , 79, 37-43		49
1274	Adult acute lymphoblastic leukaemia. 2004 , 50, 223-61		61
1273	Tyrosine kinase inhibitors in cancer therapy. 2004 , 37, 618-35		161
1272	Familial pancreatic carcinoma in Jews. 2004 , 3, 233-40		31
1271	[Clinical research in the "acute and chronic leukemias" competence network]. 2004 , 45, 384-92		0
1270	Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. 2004 , 83, 258-64		20
1269	Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling-evaluation of risks and benefits. 2004 , 83, 286-94		7
1268	Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. 2004 , 53, 102-6		113
1267	Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. 2004 , 53, 433-8		42

1266	Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. 2004 , 54, 290-4	97
1265	[Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia]. 2004 , 25, 127-34	1
1264	[Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)]. 2004 , 25, 428-35	1
1263	Abl: the prototype of oncogenic fusion proteins. 2004 , 61, 2897-911	18
1262	Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. 2004 , 28 Suppl 1, S61-3	27
1261	Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis. 2004 , 2, 26	26
1260	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. 2004 , 124, 166-78	28
1259	Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature. 2004 , 75, 231-8	16
1258	Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. 2004 , 76, 275-8	34
1257	ABL oncogene amplification with p16(INK4a) gene deletion in precursor T-cell acute lymphoblastic leukemia/lymphoma: report of the first case. 2004 , 76, 360-3	14
1256	Inherited predisposition to cancer: a historical overview. 2004 , 129C, 5-22	38
1255	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. 2004 , 100, 116-21	97
1254	Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: Problems in diagnosis, surveillance, and management. 2004 , 100, 53-64	65
1253	Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. 2004 , 100, 1459-71	35
1252	Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. 2004 , 101, 3-27	886
1251	Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. 2004 , 100, 2396-402	32
1250	Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. 2004 , 101, 979-88	30
1249	Imatinib mesylate in chordoma. 2004 , 101, 2086-97	222

1248	Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells. 2004 , 62, 35-45	13
1247	Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. 2004 , 110, 251-9	27
1246	Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha. 2004 , 111, 317-21	19
1245	Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. 2004 , 23, 139-52	45
1244	Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. 2004 , 804, 431-4	56
1243	Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. 2004 , 28, 415-9	16
1242	Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines. 2004 , 28, 405-8	16
1241	Lessons learned from the development of imatinib. 2004 , 28 Suppl 1, S29-38	47
1240	Imatinib mesylate (STI571) for myeloid malignancies other than CML. 2004 , 28 Suppl 1, S53-9	16
1239	Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. 2004 , 28 Suppl 1, S47-52	22
1238	A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. 2004 , 28 Suppl 1, S65-9	21
1237	Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. 2004 , 28, 657-60	9
1236	Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells. 2004 , 28, 623-9	15
1235	Clinical results with imatinib in chronic myeloid leukaemia. 2004 , 28 Suppl 1, S3-9	8
1234	Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. 2004 , 28, 613-8	17
1233	Monitoring of plasma imatinib concentration for the effective treatment of CML patients. 2004 , 28, 1117-8	3
1232	Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms. 2004 , 28, 1153-7	9
1231	Targeting wide-range oncogenic transformation via PU24FCL, a specific inhibitor of tumor Hsp90. 2004 , 11, 787-97	144

1230	Effect of St John's wort on imatinib mesylate pharmacokinetics. 2004 , 76, 323-9	154
1229	Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. 2004 , 45, 1775-81	38
1228	A closer look at specific therapeutic strategies in leukemia. 2004 , 45, 1767-73	1
1227	Systemic therapies for hepatocellular carcinoma. 2004 , 13, 1555-68	41
1226	Reduced dose imatinib mesylate therapy for chronic myeloid leukemia. 2004 , 45, 2363-4	3
1225	Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. 2004 , 45, 2187-95	30
1224	Imatinib as a paradigm of targeted therapies. 2004 , 91, 1-30	253
1223	Spotlight on imatinib mesylate in chronic myeloid leukemia. 2004 , 18, 207-10	3
1222	Chemical genomics: probing protein function using small molecules. 2004 , 4, 313-20	9
1221	Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. 2004 , 22, 935-42	391
1220	Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. 2004 , 103, 1202-10	195
1219	Platelets and Megakaryocytes. 2004 ,	4
1218	C-H to N substitution dramatically alters the sequence-specific DNA alkylation, cytotoxicity, and expression of human cancer cell lines. 2004 , 126, 3406-7	20
1217	Natural history and staging of chronic myelogenous leukemia. 2004 , 18, 569-84, viii	65
1216	Imatinib therapy in chronic myeloid leukemia. 2004 , 18, 605-17, viii	15
1215	Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). 2004 , 45, 695-8	99
1214	Efficient silencing of bcr/abl oncogene by single- and double-stranded siRNAs targeted against b2a2 transcripts. 2004 , 43, 16134-41	11
1213	Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. 2004 , 50, 1205-13	109

1212	Investigational strategies in chronic myelogenous leukemia. 2004 , 18, 619-39, ix	6
1211	Clinical resistance to imatinib: mechanisms and implications. 2004 , 18, 641-56, ix	69
1210	Un nouvel espoir pour les tumeurs stromales gastro-intestinales. 2004 , 3, 109-112	
1209	Autologous hematopoietic cell transplantation for chronic myelogenous leukemia. 2004 , 18, 715-32, xi	4
1208	Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. 2004 , 18, 703-13, xi	8
1207	[Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase: Glivec. A case report]. 2004 , 27, 107-9	5
1206	Clonal evolution in chronic myelogenous leukemia. 2004 , 18, 671-84, x	67
1205	Current approach to diagnosis and management of chronic lymphocytic leukemia. 2004 , 79, 388-98	24
1204	Biomarkers in cancer management: a crucial bridge toward personalized medicine. 2004 , 1, 305-311	1
1203	Hypereosinophilic syndrome: case presentation and update. 2004 , 113, 50-8	48
1202	The biology of Kit in disease and the application of pharmacogenetics. 2004 , 114, 13-9; quiz 20	100
1201	The BCR-ABL story: bench to bedside and back. 2004 , 22, 247-306	303
1200	A current perspective on local excision of rectal cancer. 2004 , 4, 26-35; discussion 36-7	18
1199	Animal models of chronic myelogenous leukemia. 2004 , 18, 525-43, vii	9
1198	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. 2004 , 47, 6239-47	151
1197	The Role of Imatinib in the Treatment of Chronic Myelogenous Leukemia. 2004 , 3, 337-348	
1196	Death by Abl: a matter of location. 2004 , 59, 165-92	42
1195	Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. 2004 , 44, 158-62	112

1194 Biopharmaceutical Technologies and Processes in Drug Development. **2004**, 35-95

1193 Management of Prostate Cancer. **2004**, 2

1192 Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. **2004**, 45, 655-60 45

1191 Anticancer Drug Development Guide. **2004**, 18

1190 Accelerated and blastic phases of chronic myelogenous leukemia. **2004**, 18, 753-74, xii 29

1189 Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. **2004**, 10, 3528-34 44

1188 Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells. **2004**, 67, 310-9 16

1187 Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. **2004**, 3, 209-17 96

1186 [Lichenoid cutaneous reaction to imatinib]. **2004**, 131, 571-3 15

1185 Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. **2004**, 6, 503-12 39

1184 Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. **2004**, 110, 206-21 274

1183 FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. **2004**, 40, 707-21, discussion 722-4 54

1182 Multi-species toxicology approaches for oncology drugs: the US perspective. **2004**, 40, 907-13 26

1181 Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. **2004**, 63, 934-9 33

1180 Proteomic approaches in cancer risk and response assessment. **2004**, 10, 59-64 49

1179 The RET proto-oncogene: a potential target for molecular cancer therapy. **2004**, 10, 351-7 38

1178 Targeting promiscuous signaling pathways in cancer: another Notch in the bedpost. **2004**, 10, 591-8 14

1177 Part II: Vaccines for haematological malignant disorders. **2004**, 5, 727-37 31

1176	In silico biological function attribution: a different perspective. 2004 , 2, 30-37	1
1175	Chronic myeloid leukaemia. 2004 , 32, 70-71	
1174	Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. 2004 , 43, 12931-6	82
1173	Predictors of 1-year survival assessed at the time of bone marrow transplantation. 2004 , 45, 378-85	30
1172	Emerging treatments in acute myeloid leukaemia. 2004 , 9, 55-71	14
1171	Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. 2004 , 15, 599-602	32
1170	KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. 2004 , 28, 676-8	83
1169	Surgical interventions during STI 571 treatment of metastatic GIST: experience in six patients. 2004 , 104, 683-9	1
1168	Inflammatory myopathy associated with imatinib mesylate therapy. 2004 , 5, 119-21	7
1167	c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue). 2004 , 28, 479-88	179
1166	The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. 2004 , 11, 51-7	61
1165	Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors. 2004 , 16 Suppl 4, 55-8	4
1164	Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. 2004 , 103, 2266-75	62
1163	Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. 2004 , 104, 4202-9	108
1162	Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. 2004 , 103, 1966-7; author reply 1967	41
1161	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. 2004 , 103, 2873-8	344
1160	Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. 2004 , 104, 1094-9	148
1159	Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. 2004 , 104, 1931-9	110

1158	Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. 2004 , 104, 3507-12	150
1157	Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. 2004 , 103, 451-5	92
1156	NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. 2004 , 103, 4622-9	75
1155	Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. 2004 , 103, 538-44	147
1154	In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. 2004 , 103, 208-15	88
1153	A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. 2004 , 103, 2299-307	92
1152	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. 2004 , 103, 2284-90	60
1151	Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. 2004 , 103, 3549-51	47
1150	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. 2004 , 103, 4396-407	458
1149	Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. 2004 , 103, 4666-8	53
1148	Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. 2004 , 103, 2929-35	49
1147	Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. 2004 , 103, 3521-8	143
1146	Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. 2004 , 104, 509-18	102
1145	Active transport of imatinib into and out of cells: implications for drug resistance. 2004 , 104, 3739-45	539
1144	CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. 2004 , 104, 1442-9	68
1143	Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. 2004 , 104, 1979-88	144
1142	FIP1L1-PDGFR α fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. 2004 , 104, 3038-45	248
1141	Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. 2004 , 104, 4245-51	85

1140	Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. 2004 , 104, 1898-906	127
1139	Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. 2004 , 104, 2926-32	206
1138	Induction of imatinib metabolism by hypericum perforatum. 2004 , 104, 1229-30	30
1137	Hyper-CVADinib for Ph+ ALL. 2004 , 103, 4377-4377	
1136	Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. 2004 , 104, 2532-9	170
1135	Cell Cycle and Growth Control: Current Clinical Applications. 2004 , 667-703	1
1134	Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. 2005 , 27, 634-40	84
1133	Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. 2005 , 12, 7-13	31
1132	Update on the biology and therapy of gastrointestinal stromal tumors. 2005 , 12, 44-56	79
1131	[Articles of the Hungarian Medical Journal from May, 2005]. 2005 , 146, 825-1228	
1130	Dissecting cancer pathways and vulnerabilities with RNAi. 2005 , 70, 435-44	27
1129	Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. 2005 , 70, 73-81	34
1128	Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia. 2005 , 12, 55-61	11
1127	"Lineage addiction" in human cancer: lessons from integrated genomics. 2005 , 70, 25-34	24
1126	Screens using RNAi and cDNA expression as surrogates for genetics in mammalian tissue culture cells. 2005 , 70, 449-59	20
1125	Targeted lung cancer therapy: what have we learned from gefitinib?. 2005 , 2, 1-2	3
1124	Resistance to imatinib: mechanisms and management. 2005 , 3, 757-68	44
1123	Acute promyelocytic leukemia: a model of molecular target based therapy. 2005 , 10 Suppl 1, 270-80	15

1122	Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines. 2005 , 14, 645	3
1121	New approaches to drug development in pediatric oncology. 2005 , 11, 324-30	16
1120	After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. 2005 , 105, 22-30	50
1119	Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. 2005 , 105, 3303-11	209
1118	Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. 2005 , 105, 2093-8	180
1117	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. 2005 , 105, 986-93	449
1116	Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. 2005 , 105, 2473-9	235
1115	PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. 2005 , 105, 3995-4003	59
1114	The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells. 2005 , 105, 4895-6	4
1113	CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. 2005 , 105, 2941-8	243
1112	Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. 2005 , 105, 3127-32	244
1111	The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. 2005 , 105, 4894-5; author reply 4895	28
1110	Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. 2005 , 105, 4893-4	34
1109	The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. 2005 , 105, 4898; author reply 4899	27
1108	Patients with thalassemia in the United States. 2005 , 105, 4896-7	5
1107	In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. 2005 , 106, 2520-6	121
1106	The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. 2005 , 106, 3206-13	102
1105	Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. 2005 , 106, 2436-43	56

1104	Does the FLIPI apply to grade 3 follicular lymphoma?. 2005 , 105, 4892; author reply 4892-3	10
1103	Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. 2005 , 385, 399-408	352
1102	Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. 2005 , 29, 233-4	25
1101	Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha. 2005 , 29, 173-8	14
1100	The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line. 2005 , 29, 793-802	10
1099	Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission. 2005 , 29, 1097-8	7
1098	The hypereosinophilic syndromes: still more heterogeneity. 2005 , 17, 679-84	35
1097	Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells. 2005 , 1044, 168-77	8
1096	Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. 2005 , 82, 343-6	16
1095	FLT3 tyrosine kinase inhibitors. 2005 , 82, 100-7	62
1094	Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case. 2005 , 35, 157-60	2
1093	Effects of imatinib on normal hematopoiesis and immune activation. 2005 , 23, 1082-8	60
1092	In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. 2005 , 65, 4500-5	904
1091	Imatinib inhibits the functional capacity of cultured human monocytes. 2005 , 83, 48-56	32
1090	Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. 2005 , 20, 818-24	105
1089	Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. 2005 , 46, 540-50	15
1088	CD117+ small cell lung cancer lacks the asp 816-->val point mutation in exon 17. 2005 , 47, 517-22	17
1087	Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. 2005 , 96, 48-53	57

1086	Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. 2005 , 96, 333-9	42
1085	Biology and management of relapsed acute myeloid leukaemia. 2005 , 129, 18-34	72
1084	Lack of clinical efficacy of imatinib in metastatic melanoma. 2005 , 92, 1398-405	224
1083	Timeline: Chemotherapy and the war on cancer. 2005 , 5, 65-72	1259
1082	Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético). 2005 , 36, 301-6	7
1081	Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. 2005 , 36, 417-24	30
1080	KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). 2005 , 19, 27-30	57
1079	Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG. 2005 , 19, 1198-206	86
1078	Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. 2005 , 19, 1184-91	69
1077	Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. 2005 , 19, 1590-6	38
1076	Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. 2005 , 19, 1985-7	7
1075	On the TRAIL of a new therapy for leukemia. 2005 , 19, 2195-202	48
1074	Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. 2005 , 24, 1-10	96
1073	An enriched look at tyrosine phosphorylation. 2005 , 23, 36-7	19
1072	Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities. 2005 , 34, 449-59	19
1071	BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. 2005 , 159, 164-7	22
1070	Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes. 2005 , 152, 139-50	22
1069	AMN107: tightening the grip of imatinib. 2005 , 7, 117-9	87

1068	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. 2005 , 7, 387-97	2353
1067	EGF receptor inhibition: attacks on multiple fronts. 2005 , 7, 287-8	35
1066	Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. 2005 , 7, 425-31	130
1065	Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. 2005 , 33, 550-7	34
1064	RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. 2005 , 33, 767-75	63
1063	Enhanced CML stem cell elimination in vitro by bryostatins priming with imatinib mesylate. 2005 , 33, 1140-6	16
1062	Conventional and new treatment options for myelofibrosis with myeloid metaplasia. 2005 , 32, 422-31	6
1061	Other compounds and targets in non-small cell lung cancer. 2005 , 32, S30-6	5
1060	Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. 2005 , 74, 89-90	39
1059	Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. 2005 , 74, 121-3	53
1058	Imatinib in pregnancy. 2005 , 74, 535-7	39
1057	Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?. 2005 , 75, 89-90	6
1056	Protein phosphorylation in signaling--50 years and counting. 2005 , 30, 286-90	493
1055	Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. 2005 , 55, 757-65	28
1054	Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. 2005 , 25, 325-34	28
1053	Guía de práctica clínica en los tumores estromales gastrointestinales. 2005 , 78, 1-13	2
1052	COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?. 2005 , 96, 159-67	48
1051	17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types. 2005 , 96, 381-8	19

1050	Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. 2005 , 205, 218-27	15
1049	Chronic myelomonocytic leukemia: lost in classification?. 2005 , 23, 26-33	29
1048	Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from calophyllum brasiliense that acts by induction of apoptosis. 2005 , 113, 158-65	38
1047	Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. 2005 , 113, 515-24	167
1046	Expression patterns of potential therapeutic targets in prostate cancer. 2005 , 113, 619-28	130
1045	In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. 2005 , 113, 849-56	33
1044	Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. 2005 , 116, 36-44	119
1043	Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. 2005 , 103, 368-76	73
1042	New approaches in the treatment of myelofibrosis. 2005 , 103, 32-43	14
1041	Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines. 2005 , 103, 102-10	12
1040	Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. 2005 , 103, 2099-108	57
1039	Gastrointestinal stromal tumor: 5 years later. 2005 , 104, 1781-8	157
1038	Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia. 2005 , 79, 79-80	8
1037	Slow infusion of platelets: a possible alternative in the management of refractory thrombocytopenic patients. 2005 , 79, 80	11
1036	Not all Noni liquid dietary supplements are created equal. 2005 , 79, 81	5
1035	Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. 2005 , 79, 80-1	20
1034	Acquired hemophilia in a patient affected by acute myeloid leukemia. 2005 , 79, 81-2	7
1033	Hyper eosinophilic syndrome: an update. 2005 , 80, 148-57	87

1032 Protein Interaction-Targeted Drug Discovery. **2005**, 323-345

1031 Chronic myeloid leukemia: a model for oncology. **2005**, 84, 487-97

43

1030 Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. **2005**, 55, 379-386

164

1029 Additive apoptotic effect of STI571 with the cytoprotective agent amifostine in K-562 cell line. **2005**, 55, 602-8

2

1028 Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. **2005**, 56, 358-60

32

1027 Novel approaches in the therapy of metastatic renal cell carcinoma. **2005**, 23, 202-12

178

1026 Potentiality of combined hepatocellular and intrahepatic cholangiocellular carcinoma originating from a hepatic precursor cell: Immunohistochemical evidence. **2005**, 32, 52-7

30

1025 Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis. **2005**, 10, 743-58

13

1024 The synergistic inhibitory effect of STI571 in combination with arsenic trioxide (As₂O₃) on multidrug-resistant leukemic cells. **2005**, 2, 671-674

1023 Imatinib mesylate and its potential implications for gynecologic cancers. **2005**, 6, 115-20

9

1022 The potential for molecular therapeutic targets in Ewing's sarcoma. **2005**, 6, 461-71

11

1021 New agents in the treatment of childhood leukemias and myelodysplastic syndromes. **2005**, 7, 399-405

3

1020 A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. **2005**, 90, 157-63

76

1019 EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. **2005**, 22, 1757-61

17

1018 In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. **2005**, 63, 385-94

35

1017 Targeted therapy: for kids, too. **2005**, 45, 623-34

2

1016 Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. **2005**, 14, 545-53

25

1015 Targeted therapy for hematologic malignancies. **2005**, 12, 82-90

8

1014	Clinical Aspects of Imatinib Therapy. 2005 , 391-410	1
1013	Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor. 2005 , 20, 512-5	17
1012	BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. 2005 , 65, 3264-72	103
1011	Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia. 2005 , Volume 1-Issues 1 & 2, 0-0	
1010	Bibliography. 2005 , 649-682	
1009	Complexity of cancer as a genetic disease. 2005 ,	
1008	Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. 2005 , 11, 581-611	69
1007	[Molecular mechanisms involved in adrenocortical tumorigenesis]. 2005 , 49, 753-68	
1006	in vivo Cardiac Gene Transfer of Dominant Negative IKK-beta Reduces Myocardial Inflammation, Apoptosis, and Infarction after Ischemia-Reperfusion Injury. 2005 , 35, 206	3
1005	Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. 2005 , 23, 3288-93	60
1004	Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. 2005 , 65, 8224-32	50
1003	Treatment of endocrine pancreatic tumors. 2005 , 44, 329-38	5
1002	Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. 2005 , 5, 615-23	28
1001	Pharmacogenomics steps toward personalized medicine. 2005 , 2, 325-337	60
1000	Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. 2005 , 288, G907-13	109
999	Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor. 2005 , 1, 93-108	5
998	Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. 2005 , 9, 161-9	12
997	Receptor tyrosine kinases and anticancer therapy. 2005 , 11, 1139-49	36

996	Personalized medical treatment strategies for patients with chronic myeloid leukemia. 2005 , 5, 343-53	
995	Src kinases as targets for B cell acute lymphoblastic leukaemia therapy. 2005 , 9, 329-41	7
994	Best Practice No 185. Cytological and molecular diagnosis of lymphoma. 2005 , 58, 561-7	27
993	Getting at MYC through RAS. 2005 , 11, 4278-81	29
992	Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. 2005 , 11, 4460-8	92
991	Imatinib-induced regression of AIDS-related Kaposi's sarcoma. 2005 , 23, 982-9	147
990	Targeted therapy with imatinib: hits and misses?. 2005 , 23, 8-10	36
989	In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. 2005 , 11, 7508-15	137
988	Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer. 2005 , 23, 410-2	7
987	Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. 2005 , 11, 1928-40	71
986	The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. 2005 , 65, 2577-82	306
985	Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. 2005 , 11, 4182-90	668
984	The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. 2005 , 4, 6-13	178
983	Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. 2005 , 64, 1126-31	84
982	Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib. 2005 , 43, 267-73	5
981	Ein neuer Akt in der Tumorthherapie? Inhibition des PI3K/Akt-Kinasewegs als neue Therapieoption bei Tumorerkrankungen. 2005 , 26, 105-112	
980	Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. 2005 , 171, 1279-85	192
979	Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. 2005 , 141, 368-70	59

978	Risks and benefits of phase 1 oncology trials, revisited. <i>New England Journal of Medicine</i> , 2005 , 352, 930-39.2	78
977	Regulating academic-industrial research relationships--solving problems or stifling progress?. <i>New England Journal of Medicine</i> , 2005 , 353, 1060-5	59.2 116
976	Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features. 2005 , 46, 663-70	17
975	Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. 2005 , 46, 781-4	20
974	Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. 2005 , 211, 363-5	35
973	RNA interference for treating haematological malignancies. 2005 , 5, 1585-92	3
972	Problems and promises of targeted therapy for Hodgkin's lymphoma. 2005 , 2, 2-3	1
971	Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. 2005 , 102, 3395-400	283
970	Molecular Basis of Thyroid Cancer. 2005 ,	1
969	Digital karyotyping technology: exploring the cancer genome. 2005 , 5, 917-25	6
968	Recent advances in targeted therapy of human myelogenous leukaemia. 2005 , 9, 1147-63	2
967	Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?. 2005 , 14, 1063-6	1
966	ERBB2 in pediatric cancer: innocent until proven guilty. 2005 , 10, 508-17	25
965	Emerging targeted treatments for malignant glioma. 2005 , 10, 845-54	4
964	Inhibition of natural type I IFN-producing and dendritic cell development by a small molecule receptor tyrosine kinase inhibitor with Flt3 affinity. 2005 , 175, 3674-80	52
963	Prevalence of KIT expression in human tumors: gallbladder cancer. 2005 , 23, 5268-71; author reply 5271-2	0
962	Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. 2005 , 65, 4471-4	83
961	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. 2005 , 102, 11011-6	487

960	Design issues of randomized phase II trials and a proposal for phase II screening trials. 2005 , 23, 7199-206	279
959	Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. 2005 , 23, 7583-93	82
958	The kinase inhibitor imatinib mesylate inhibits TNF- α production in vitro and prevents TNF-dependent acute hepatic inflammation. 2005 , 102, 13622-7	107
957	KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. 2005 , 23, 49-57	184
956	Altered IFN γ signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets. 2005 , 65, 2914-20	7
955	Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib. 2005 , 23, 3855-6; author reply 3857-8	14
954	Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. 2005 , 23, 6838-45	513
953	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. 2005 , 65, 1642-6	569
952	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. 2005 , 97, 880-7	402
951	ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. 2005 , 23, 4100-9	308
950	ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. 2005 , 65, 3538-41	110
949	T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. 2005 , 4, 1167-74	61
948	Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. 2005 , 71, 131-40	24
947	Modern diagnosis and treatment of primary eosinophilia. 2005 , 114, 52-60	39
946	Therapeutic targeting of receptor tyrosine kinases in lung cancer. 2005 , 9, 533-59	20
945	Molecularly targeted therapy for gastrointestinal cancer. 2005 , 5, 171-93	73
944	Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. 2005 , 11, 6987-93	88
943	EGFR gene mutations: a call for global x global views of cancer. 2005 , 97, 326-8	23

942	Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. 2005 , 19, 960-2	56
941	The development and application of imatinib. 2005 , 4, 183-91	29
940	BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?. 2005 , 4, 1761-6	34
939	The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. 2005 , 106, 3377-9	319
938	Detection of BCR-ABL mutations and resistance to imatinib mesylate. 2006 , 125, 93-106	40
937	A Phase I Clinical Trial Evaluating Imatinib Mesylate (Gleevec) in Tumor-Bearing Cats. 2005 , 19, 860-864	31
936	Cutaneous side-effects of kinase inhibitors and blocking antibodies. 2005 , 6, 491-500	429
935	Psychosocial function after hematopoietic stem cell transplantation. 2005 , 46, 34-40	25
934	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. 2005 , 23, 8081-92	551
933	Imatinib and regression of type 2 diabetes. <i>New England Journal of Medicine</i> , 2005 , 352, 1049-50	59.2 101
932	The development of imatinib as a therapeutic agent for chronic myeloid leukemia. 2005 , 105, 2640-53	1027
931	[From biology to innovating treatments for tumors: a long struggle]. 2005 , 63, 7-9	
930	Recent studies in novel therapy for metastatic sarcomas. 2005 , 19, 573-90, viii	5
929	C40 - Expression du r�cepteur de la tyrosine kinase c-kit dans les myofibromatoses infantiles : une nouvelle voie th�rapeutique ?. 2005 , 132, 26	
928	Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. 2005 , 80, 390-402	46
927	P50 - �ruption photod�clench�e par l'imatinib. 2005 , 132, 101	
926	Targeted therapies for prostate cancer. 2005 , 9, 283-98	10
925	Cytogenetic testing for therapeutic indication in cancer. 2005 , 5, 23-9	

924	Imatinib mesylate in the treatment of gastrointestinal stromal tumour. 2005 , 6, 105-13	11
923	Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. 2005 , 9, 1217-33	118
922	Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer. 2005 , 5, 141-8	17
921	Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. 2005 , 5, 293-302	48
920	Molecular genetics of acute lymphoblastic leukemia. 2005 , 23, 6306-15	281
919	Gastrointestinal stromal tumors. 2005 , 19, 547-64, vii	26
918	Requirement of SRC-family tyrosine kinases in fat accumulation. 2005 , 44, 14455-62	22
917	Target-specific cancer treatment: chronic granulocytic leukemia as a model. 2005 , 60, 49-53	
916	Pharmacogenetics/genomics and personalized medicine. 2005 , 14 Spec No. 2, R207-14	140
915	Specific adenine alkylation by pyrrole-imidazole CBI conjugates. 2005 , 127, 13890-5	23
914	Cancer therapy: can the challenge be MET?. 2005 , 11, 284-92	200
913	Rehabilitation of cancer through oncogene inactivation. 2005 , 11, 316-21	24
912	Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. 2005 , 53, S240-3	39
911	The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. 2005 , 53, 291-302	38
910	Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. 2005 , 36, 91-100	12
909	Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. 2005 , 36, 242-9	62
908	Imatinib may be useful in the management of patients with glioblastoma. 2005 , 65, 1205-6	2
907	Suicide is probably more common in untreated youths than in those receiving treatment: the need for a retrospective epidemiological study. 2005 , 65, 1204-5	2

906	Mutational analysis of gene families in human cancer. 2005 , 15, 5-12	40
905	Resistance to tyrosine kinase inhibitors: calling on extra forces. 2005 , 8, 119-29	33
904	Tailoring Ras-pathway--inhibitor combinations for cancer therapy. 2005 , 8, 369-80	50
903	Antitumor activity of imatinib mesylate in neuroblastoma xenografts. 2005 , 228, 211-9	20
902	Identification of cancer genes by mutational profiling of tumor genomes. 2005 , 579, 1884-90	20
901	Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic?. 2005 , 32, 657-62	13
900	Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?. 2005 , 45, 762-8	34
899	Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia. 2005 , 81, 242-5	22
898	Clinical pharmacokinetics of imatinib. 2005 , 44, 879-94	435
897	Improving outcomes in advanced malignant melanoma: update on systemic therapy. 2005 , 65, 733-43	31
896	Novel biological therapies for the treatment of multiple myeloma. 2005 , 18, 619-34	40
895	A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. 2005 , 46, 1999-2003	20
894	Leucmie myloïde chronique. 2005 , 2, 187-205	5
893	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. <i>New England Journal of Medicine</i> , 2005 , 353, 2012-24	59.2 1211
892	[Optimizing current drugs]. 2005 , 63, 17-24	0
891	Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. 2005 , 80, 681-98	39
890	Ewing's sarcoma and primitive neuroectodermal family of tumors. 2005 , 19, 501-25, vi-vii	109
889	The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. 2005 , 106, 1207-9	399

888	Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. 2005 , 102, 8287-92		97
887	Inhibitors of Protein Kinases and Protein Phosphates. 2005 ,		1
886	Myeloid Leukemia. 2005 ,		
885	Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. 2005 , 39, 2136-8		42
884	Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. 2005 , 45, 357-84		107
883	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. 2005 , 7, R570-9		94
882	Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. <i>New England Journal of Medicine</i> , 2006 , 354, 2531-41	59.2	1414
881	Mutation of the PIK3CA oncogene in human cancers. 2006 , 94, 455-9		372
880	Protein Tyrosine Kinases. 2006 ,		4
879	Pharmacogenomics of acute leukemia. 2006 , 46, 317-53		28
878	Principles of Targeted and Biological Therapies. 2006 , 73-90		
877	Cancer Drug Resistance. 2006 ,		17
876	Chronic myeloid leukemia: diagnosis and treatment. 2006 , 81, 973-88		140
875	Orphan drug designation and pharmacogenomics: options and opportunities. 2006 , 20, 71-9		8
874	Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm. 2006 , 10, 67-76		32
873	Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. 2006 , 47, 1427-30		9
872	Emerging drugs in chronic myelogenous leukaemia. 2006 , 11, 651-64		12
871	Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. 2006 , 47, 1747-53		30

870	Cell Communication in Nervous and Immune System. 2006,	2
869	The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. 2006, 13, 15-25	100
868	JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?. 2006, 47, 177-94	43
867	Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. 2006, 47, 1651-64	4
866	CYP3A4 and MDR Mediated Interactions in Drug Therapy. 2006, 23, 125-163	7
865	Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. 2006, 49, 1006-15	54
864	JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. 2006, 8, 397-411; quiz 526	65
863	Novel agents for chronic myeloid leukemia: from imatinib to dasatinib and nilotinib: overcoming resistance. 2006, 3, 519-523	
862	Host genetics influence tumour metastasis. 2006, 6, 141-6	105
861	Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?. 2006, 81, 404-16	8
860	KIT mutations in mastocytosis and their potential as therapeutic targets. 2006, 26, 575-92	38
859	Desensitization to imatinib in patients with leukemia. 2006, 97, 216-22	25
858	Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. 2006, 2006, 233-9, 510	41
857	Recent advances in the treatment of malignant astrocytoma. 2006, 24, 1253-65	258
856	Targeting tyrosine kinases in cancer: the second wave. 2006, 312, 1175-8	380
855	Long-Term Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation in First Chronic Phase of Chronic Myeloid Leukemia. 2006, 1, 123-129	
854	Pharmacokinetic considerations in the treatment of CNS tumours. 2006, 45, 871-903	53
853	The new era in cancer research. 2006, 312, 1162-5	221

852	Expression of tyrosine kinase receptors in lung carcinoids. 2006 , 27, 153-7	13
851	Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. 2006 , 77, 11-6	59
850	Hematological disorders. 2006 , 3, 497-498	
849	Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. 2006 , 24, 16-24	1408
848	Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. 2006 , 5, 3105-12	23
847	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. 2006 , 108, 1809-20	998
846	[Targeted therapies in pediatric oncology: a new therapeutic approach?]. 2006 , 13, 189-94	
845	[Hospital network in pediatric oncology]. 2006 , 13, 635-7	
844	Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance. 2006 , 144, 85-92	10
843	Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. 2006 , 12, 102-10	42
842	Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells. 2006 , 342, 1405-12	10
841	Synergistic effects of protein tyrosine kinase inhibitor genistein with camptothecins against three cell lines in vitro. 2006 , 233, 255-64	30
840	BNP as a marker of the heart failure in the treatment of imatinib mesylate. 2006 , 243, 16-22	47
839	Targeted therapies in melanoma. 2006 , 32, 524-31	16
838	Oncogene addiction: role of signal attenuation. 2006 , 11, 752-4	9
837	Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. 2006 , 42, 864-70	19
836	Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). 2006 , 42, 2277-85	82
835	Evidence of recurrent gene fusions in common epithelial tumors. 2006 , 12, 529-36	26

834	Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. 2006 , 603, 74-82	17
833	Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. 2006 , 37, 755-63	56
832	Molecular targets and the treatment of myeloid leukemia. 2006 , 88, 216-24	25
831	Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation. 2006 , 38, 3231-2	5
830	Treating imatinib-resistant leukemia: the next generation targeted therapies. 2006 , 6, 918-30	21
829	Bcr-Abl Kinase Inhibitors. 2006 , 407-444	4
828	Chronic myelogenous leukemia: from molecular biology to clinical aspects and novel targeted therapies. 2006 , 73, 178-92	9
827	Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era. 2006 , 11, 209-20	9
826	Glivec® (Gleevec® , Imatinib, STI571). 2006 , 145-160	4
825	Molecular genetics of acute lymphoblastic leukemia. 272-297	
824	Intracellular Signaling in Cancer. 2006 ,	
823	Oncogenes. 2006 ,	
822	Kit Protein (CD 117) and Proliferation Index (Ki-67) Evaluation in Well and Poorly Differentiated Neuroendocrine Tumors. 2006 , 92, 531-535	12
821	Precision weapons. 2006 , 6, S22-S23	
820	Advances in malignant melanoma: genetic insights from mouse and man. 2006 , 11, 928-42	11
819	Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. 2006 , 108, 1478-84	189
818	Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. 2006 , 107, 205-12	113
817	Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. 2006 , 108, 3477-83	172

816	Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. 2006 , 111, 233-49	7
815	Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups. 2006 , 107, 2079-89	29
814	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomyacin B. 2006 , 107, 1591-8	44
813	Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. 2006 , 107, 1582-90	81
812	A common phosphotyrosine signature for the Bcr-Abl kinase. 2006 , 107, 4888-97	81
811	STAT5 signaling is required for the efficient induction and maintenance of CML in mice. 2006 , 107, 4917-25	85
810	The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. 2006 , 107, 4039-46	127
809	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). 2006 , 108, 1497-503	287
808	Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. 2006 , 108, 3406-13	62
807	Gastrointestinal Stromal Tumors. 2006 , 418-429	
806	Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. 2006 , 15, 1205	2
805	Leucémie myéloïde chronique. 2006 , 1, 1-13	1
804	c-Myc and downstream targets in the pathogenesis and treatment of cancer. 2006 , 1, 305-26	29
803	Rational Development of Targeted Cancer Therapies Using Biomarkers. 2006 , 37, 482-489	
802	Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia. 2006 , 6, 526-8	2
801	Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. 2006 , 12, 111-28	18
800	Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach. 2006 , 28, 1361	1
799	A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. 2006 , 15, 101-8	28

798	Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region. 2006 , 25, 70-6	23
797	Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. 2006 , 29, 12-3	85
796	Imatinib mesylate-induced acute hepatitis with autoimmune features. 2006 , 18, 1235-7	17
795	Molecular regulation of cytoskeletal rearrangements during T cell signalling. 2006 , 43, 219-44	6
794	Multicellular tumour spheroid as a model for evaluation of [18F]FDG as biomarker for breast cancer treatment monitoring. 2006 , 6, 6	13
793	Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). 2006 , 33, 280-5	24
792	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. 2006 , 11, 687-92	27
791	From genes to therapy: the case of Philadelphia chromosome-positive leukemias. 2002 , 963, 306-12	7
790	Follicular acneiform eruption induced by imatinib. 2006 , 20, 1368-70	13
789	Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment. 2006 , 23, 175-8	20
788	Targeting leukemic fusion proteins with small interfering RNAs: recent advances and therapeutic potentials. 2006 , 27, 273-81	23
787	Detection of COL1A1-PDGFB fusion transcripts and platelet-derived growth factor alpha and beta receptors in giant cell fibroblastoma of the postsacrococcygeal region. 2006 , 154, 983-7	7
786	In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. 2006 , 36, 402-8	19
785	Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy. 2006 , 62, 27-34	4
784	Antitumor activity of sequence-specific alkylating agents: pyrrole-imidazole CBI conjugates with indole linker. 2006 , 97, 219-25	39
783	Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. 2006 , 97, 952-60	17
782	PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. 2006 , 97, 1351-8	124
781	Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?. 2006 , 49, 576-81	25

780	Translating in vivo diagnostics into clinical reality. 2006 , 24, 909-13	39
779	The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. 2006 , 24, 985-95	108
778	Targeted cancer therapeutics: the heartbreak of success. 2006 , 12, 881-2	29
777	Mapping normal and cancer cell signalling networks: towards single-cell proteomics. 2006 , 6, 146-55	265
776	Drug interactions in cancer therapy. 2006 , 6, 546-58	224
775	Impact of genetic diagnostics on drug development strategy. 2006 , 5, 459-62	10
774	Strategies for optimizing combinations of molecularly targeted anticancer agents. 2006 , 5, 649-59	288
773	Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFR mutations. 2006 , 19, 1157-63	36
772	EBMT activity survey 2004 and changes in disease indication over the past 15 years. 2006 , 37, 1069-85	80
771	Chronic myeloproliferative disorders: a tyrosine kinase tale. 2006 , 20, 200-5	56
770	The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. 2006 , 20, 650-7	40
769	Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. 2006 , 20, 793-9	17
768	BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. 2006 , 20, 1035-9	75
767	Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. 2006 , 20, 1162-4	75
766	Difference between hematological malignancy and solid tumor research articles published in four major medical journals. 2006 , 20, 1655-7	13
765	Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase. 2006 , 25, 493-502	21
764	Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. 2006 , 25, 4913-22	72
763	Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. 2006 , 12, 1087-9	21

762	STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. 2006 , 116, 1409-16	20
761	Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. 2006 , 144, 335-41	26
760	Kinase inhibitors in the treatment of renal cell carcinoma. 2006 , 60, 216-26	26
759	Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. 2006 , 20, 29-41	116
758	SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. 2006 , 16, 1320-3	117
757	STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. 2006 , 64, 263-71	52
756	Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures. 2006 , 30, 286-95	12
755	Discovering and validating cancer genetic dependencies: approaches and pitfalls. 2020 , 21, 671-682	19
754	Current status and perspectives of patient-derived rare cancer models. 2020 , 33, 919-929	4
753	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. 2020 , 33,	32
752	Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving Target. 2020 , 35, 791-798	4
751	First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. 2020 , 4, 2723-2735	17
750	DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma. 2020 , 54, 455-470.e5	18
749	Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance. 2020 , 26, 4040-4053	6
748	Drug Resistance in Non-Hodgkin Lymphomas. 2020 , 21,	15
747	Small molecules, big impact: 20 years of targeted therapy in oncology. 2020 , 395, 1078-1088	107
746	Gray Areas in the Gray Matter: Mutations in Glioma. 2020 , 40, 1-8	5
745	Non-Thermal Plasma Induces Antileukemic Effect Through mTOR Ubiquitination. 2020 , 9,	8

744	When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selipercatinib, a 'RET' inhibitor. 2020 , 31, 328-330	3
743	Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib. 2020 , 12, 4777-4787	2
742	Dysregulation of cancer genes by recurrent intergenic fusions. 2020 , 21, 166	8
741	The Community Oncology and Academic Medical Center Alliance in the Age of Precision Medicine: Cancer Genetics and Genomics Considerations. 2020 , 9,	2
740	Molecular Analysis of Liquid-Based Cytological Specimen Using Virtually Positive Sputum with Adenocarcinoma Cells. 2020 , 10,	5
739	A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants. 2020 , 8, 48	16
738	Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity. 2020 , 44, 1212-1223	5
737	Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type. 2020 , 25,	4
736	ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells. 2020 , 39, 3195-3205	9
735	Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. 2020 , 15, 20-30	7
734	Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. 2020 , 21,	3
733	A Bartonella Effector Acts as Signaling Hub for Intrinsic STAT3 Activation to Trigger Anti-inflammatory Responses. 2020 , 27, 476-485.e7	8
732	Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment. 2020 , 176, 113855	5
731	Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. 2020 , 12,	22
730	Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap. 2020 , 11, 443	7
729	Selective and sensitive detection of chronic myeloid leukemia using fluorogenic DNAzyme probes. 2020 , 1123, 28-35	4
728	Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved. 2020 , 112, 886-892	8
727	Fluorometric detection of single-nucleotide mutations using tandem gene amplification. 2020 , 314, 128071	2

726	Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells. 2020 , 525, 1074-1080	6
725	Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India. 2020 , 20, e437-e444	2
724	Exploring the anti-stress effects of imatinib and tetrabenazine in cold-water immersion-induced acute stress in mice. 2020 , 393, 1625-1634	1
723	ZnO/CNT@FeO induces ROS-mediated apoptosis in chronic myeloid leukemia (CML) cells: an emerging prospective for nanoparticles in leukemia treatment. 2020 , 48, 735-745	4
722	Response and Resistance to BCR-ABL1-Targeted Therapies. 2020 , 37, 530-542	90
721	Genetics and Genomics of Breast Cancer: update and translational perspectives. 2021 , 72, 27-35	7
720	Haematologists do it. 2021 , 56, 1-3	1
719	Autophagy in the physiological endometrium and cancer. 2021 , 17, 1077-1095	36
718	Designing composite cryogel carriers for tyrosine adsorption. 2021 , 254, 117622	2
717	Engineering in Medicine To Address the Challenge of Cancer Drug Resistance: From Micro- and Nanotechnologies to Computational and Mathematical Modeling. 2021 , 121, 3352-3389	13
716	Protein engineering for selective proteomics. 2021 , 60, 10-19	1
715	Challenges and Opportunities in Cancer Drug Resistance. 2021 , 121, 3297-3351	66
714	Computational and systems biology of cancer. 2021 , 1, e1005	
713	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. 2021 , 7, 15-28	27
712	Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India. 2021 , 100, 85-96	3
711	Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers. 2021 , 26, e153-e163	4
710	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. 2021 , 39, 38-53.e7	18
709	Blueprint for cancer research: Critical gaps and opportunities. 2021 , 71, 107-139	7

708	The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules. 2021 , 13, e1689	5
707	Immunomodulation by targeted anticancer agents. 2021 , 39, 310-345	44
706	Current state and future perspective of drug repurposing in malignant glioma. 2021 , 68, 92-104	18
705	Molecular diagnostics and targeted treatment approaches in pediatric oncology (literature review). 2021 , 29-33	
704	The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML. 2021 ,	
703	Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective. 2021 , 28, 10732748211038735	3
702	Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology. 2021 , 81, 445-452	2
701	Chronic Myeloid Leukemia. 2021 , 329-345	
700	Molecular Mechanisms of Distinct Diseases.	
699	Characteristics of F-FDG and F-FDOPA PET in an 8-year-old neutered male Yorkshire Terrier dog with glioma: long-term chemotherapy using hydroxyurea plus imatinib with prednisolone and immunoreactivity for PDGFR and LAT1. 2021 , 41, 163-171	2
698	The Role of Hematopoietic Stem Cell Transplantation in CML. 2021 , 159-178	
697	Cytotoxic Activity of Raphanus sativus Linn. on Selected Cancer Cell Lines and Mechanistic Pathways Predicted Through Mathematical Modeling. 2021 , 175-196	0
696	Foreword. 2021 , xi-xii	
695	RNAi screening reveals requirement for PDGFR in JEV infection.	
694	Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy. 2021 , 10,	5
693	Trends in survival of leukemia among children, adolescents, and young adults: A population-based study in Osaka, Japan. 2021 , 112, 1150-1160	3
692	Molecular Signatures of Gynecological Cancers: Clinicians Perspective. 2021 , 12, 103-110	
691	Caffeic Acid Enhances the Anti-Leukemic Effect of Imatinib on Chronic Myeloid Leukemia Cells and Triggers Apoptosis in Cells Sensitive and Resistant to Imatinib. 2021 , 22,	5

690	A Broad Overview of Signaling in -Negative Classic Myeloproliferative Neoplasms. 2021 , 13,	3
689	Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge. 2021 , 10,	4
688	Multikinase inhibitors in thyroid cancer: timing of targeted therapy. 2021 , 17, 225-234	12
687	The endangered physician-scientist and COVID-19. 2021 , 2, 100190	1
686	Current status and future outlook for patient-derived cancer models from a rare cancer research perspective. 2021 , 112, 953-961	6
685	Senescent cells and the incidence of age-related diseases. 2021 , 20, e13314	7
684	VALIDATED STABILITY INDICATING UPLC METHOD FOR AFATINIB AND ITS IMPURITIES IN PHARMACEUTICAL DOSAGE FORM. 2021 , 57, 27-39	
683	Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis. 2021 , 10, 1955-1963	3
682	Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics. 2021 , 23, 31	6
681	STABILITY ANALYSIS OF A MATHEMATICAL MODEL FOR CHRONIC MYELOID LEUKEMIA ERADICATION. 2021 , 29, 169-191	
680	Improved cell signaling analysis by biofunctionalized nanospheres and imaging flow cytometry. 2021 , 99, 1079-1090	
679	Pathway-Directed Therapy in Multiple Myeloma. 2021 , 13,	4
678	Human Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery. 2021 , 12, 650039	0
677	Can Precision Electrophile Signaling Make a Meaningful and Lasting Impression in Drug Design?. 2021 ,	0
676	JAFFAL: Detecting fusion genes with long read transcriptome sequencing.	3
675	Recent advances in understanding chronic myeloid leukemia: where do we stand?. 2021 , 10, 35	2
674	RTK Inhibitors in Melanoma: From Bench to Bedside. 2021 , 13,	7
673	Repurposing of Acriflavine to Target Chronic Myeloid Leukemia Treatment. 2021 , 28, 2218-2233	7

- 672 Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature. **2021**, 15, 114-131
- 671 Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review. **2021**, 38, 1897-1908 5
- 670 Benchmarking 50 classification algorithms on 50 gene-expression datasets.
- 669 Preclinical models and technologies to advance nanovaccine development. **2021**, 172, 148-182 3
- 668 RNA Interference Screening Reveals Requirement for Platelet-Derived Growth Factor Receptor Beta in Japanese Encephalitis Virus Infection. **2021**, 65, 3 3
- 667 Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation. **2021**, 11, 643382 5
- 666 Dasatinib-induced chylothorax: An unusual presentation of a common adverse event: A case report with literature review. **2021**, 2, 545-550
- 665 Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval. **2021**, 39, 1674-1686 2
- 664 Precision Oncology. **2021**, 1, 97-112
- 663 Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. **2021**, 194, 393-402 7
- 662 Elucidation of Ligand/Protein Interactions between BCR-ABL Tyrosine Kinase and Some Commercial Anticancer Drugs Via DFT Methods. **2021**, 20, 433-447 0
- 661 Chronic Myeloid Leukemia in a Patient with Hepatitis B Virus Infection: A Case Report. **2021**, 14, 1004-1009
- 660 IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. **2021**, 25, 457-473 3
- 659 Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. **2021**, 11, 2
- 658 Inhibition of Casein Kinase 2 induces Cell Death in Chronic Myelogenous Leukemia Cells with Different Mechanisms of Resistance to Tyrosine Kinase Inhibitors.
- 657 Evaluation of anti-EGFR potential of quinazoline derivatives using molecular docking: An in silico approach. **2021**, 1
- 656 Nanotechnology combining photoacoustic kinetics and chemical kinetics for thrombosis diagnosis and treatment. **2021**, 1
- 655 Direct interaction of the ATP-sensitive K channel by the tyrosine kinase inhibitors imatinib, sunitinib and nilotinib. **2021**, 557, 14-19 2

654	Arterial hypertension assessment in a population with chronic myeloid leukemia. 2021 , 11, 14637	1
653	Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review. 2021 , 12, 675811	4
652	Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer. 2021 , 13,	2
651	Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma. 2021 , 64, 11129-11147	1
650	DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model. 2021 , 13,	4
649	Protein flexibility and dissociation pathway differentiation can explain onset of resistance mutations in kinases.	5
648	Gene Transcription as a Therapeutic Target in Leukemia. 2021 , 22,	0
647	The Paradigm of Targeting an Oncogenic Tyrosine Kinase: Lesson from BCR-ABL.	0
646	Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia. 2021 , 26, 281-294	0
645	Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias. 2021 , 11, 694526	0
644	Studies on the Quantification of Mutation Resistance to Specific Drug Therapy in Chronic Myeloid Leukemia patients. 2021 , 4092-4100	
643	Targeting the CDK6 Dependence of Ph ⁺ Acute Lymphoblastic Leukemia. 2021 , 12,	1
642	An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer Drugs.	
641	Gene Duplication and Gene Fusion Are Important Drivers of Tumourigenesis during Cancer Evolution. 2021 , 12,	2
640	Successful determination of imatinib re-administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction. 2021 , 9, e04357	1
639	Chronic myeloid leukaemia. 2021 , 398, 1914-1926	6
638	Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. 2021 ,	3
637	Clinical Perspectives of Single-Cell RNA Sequencing. 2021 , 11,	0

636	RanBP3 Regulates Proliferation, Apoptosis and Chemosensitivity of Chronic Myeloid Leukemia Cells Mediating SMAD2/3 and ERK1/2 Nuclear Transport. 2021 , 11, 698410	0
635	Targeting Akt in cancer for precision therapy. 2021 , 14, 128	12
634	Polymeric siRNA delivery targeting integrin- α could reduce interactions of leukemic cells with bone marrow microenvironment. 2021 , 3, 100021	1
633	Using the Structural Kinome to Systematize Kinase Drug Discovery.	0
632	New insights into neuropeptides regulation of immune system and hemopoiesis: effects on hematologic malignancies. 2021 ,	
631	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. 2021 ,	1
630	Super-enhancer landscape reveals leukemia stem cell reliance on X-box binding protein 1 as a therapeutic vulnerability. 2021 , 13, eabh3462	3
629	Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. 2021 , 49, 100825	9
628	Engineering chromosome rearrangements in cancer. 2021 , 14,	1
627	Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. 2021 , 9, 957-968	26
626	Pimipitespib is effective on cecal GIST in a mouse model of familial GISTs with KIT-Asp820Tyr mutation through KIT signaling inhibition. 2021 , 123, 104692	0
625	Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. 2021 ,	1
624	Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia. 2021 , 338, 190-200	2
623	Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. 2021 , 157, 428-440	4
622	Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. 2021 , 225, 113768	8
621	Pulmonary Complications of Lung Cancer Therapies. 2022 , 931-949	
620	Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia. 2021 , 13,	10
619	Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis. 2021 , 21, 55-69	1

618 Therapeutics and DNA methylation inhibitors. **2021**, 585-595

617 Biomarkers. 1

1

616 Drug Research Leading to Imatinib and beyond to Nilotinib. 409-421

4

615 Molecular events in follicular thyroid tumors. **2004**, 122, 85-105

33

614 Obstacles and opportunities in the clinical development of targeted therapeutics. **2005**, 63, 19-41

10

613 Gastrointestinal Stromal Tumors of Gastric Origin. **2009**, 135-163

1

612 Biochip Platforms for DNA Diagnostics. **2009**, 271-297

2

611 Stem Cells and Cancer: An Introduction. **2009**, 1-31

2

610 Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer). **2010**, 205-220

1

609 Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs. **2020**, 2063, 207-234

4

608 Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data. **2020**, 2063, 235-255

13

607 Potential Therapeutic Targets for Bone Metastasis. **2004**, 187-210

1

606 The -Omics in Drug Development. **2011**, 145-173

1

605 Integrating Omics Data for Quantitative and Systems Pharmacology in Translational Oncology. **2013**, 187-206

1

604 Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. **2003**, 532, 141-51

60

603 Engineered cell-based therapies: a vanguard of design-driven medicine. **2014**, 844, 369-91

2

602 Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems. **2016**, 1386, 181-219

10

601 Central Nervous System Complications of Cancer Therapy. **2003**, 215-231

6

600	Emerging Molecular Therapies. 2004 , 569-606	1
599	Genetic Markers in Sporadic Tumors. 2004 , 73-150	0
598	Small Molecule Agents. 2007 , 337-356	1
597	Combinations of Molecular-Targeted Therapies. 2008 , 693-705	3
596	Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion. 2020 , 1202, 151-178	16
595	Gastrointestinal Stromal Tumour (GIST): Diagnosis and Treatment. 2015 , 691-717	1
594	Implementation of Exome Sequencing Assay. 2019 , 203-217	2
593	Identifying critical signaling molecules for the treatment of cancer. 2007 , 172, 5-24	2
592	Tyrosine kinase inhibitors and cancer therapy. 2007 , 172, 25-44	4
591	Monitoring Disease Response. 2007 , 143-164	3
590	Relapsed Acute Lymphoblastic Leukemia. 2008 , 275-279	3
589	Hematological Neoplasms. 2016 , 1493-1510	2
588	Imatinib mesylate. 2010 , 184, 3-20	58
587	Mesenchymale Tumoren. 2013 , 797-834	1
586	Targeted Therapy and Their Ocular Complications. 2014 , 123-132	1
585	Chemoprevention of lung cancer: new directions. 2003 , 163, 172-81; discussion 264-6	1
584	Principles of Cancer Chemotherapy. 2003 , 19-66	13
583	Cancer: Clinical Background and Key Challenges. 2011 , 29-93	1

582	Utility of Reverse-Phase Protein Array for Refining Precision Oncology. 2019 , 1188, 239-249	4
581	Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. 2007 , 17, 306-10	23
580	Growth Factor Signaling Pathways and Receptor Tyrosine Kinase Inhibitors. 2006 , 155-172	2
579	Renal Disease in Cancer Patients. 2012 , 1536-1552	1
578	Multiple Endocrine Neoplasia. 2011 , 1728-1767	6
577	A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia. 2017 , 433, 94-105	10
576	Imatinib treatment: Specific issues related to safety, fertility, and pregnancy. 2003 , 40, 21-25	5
575	Quality of life on imatinib. 2003 , 40, 31-36	1
574	Molecular monitoring of chronic myeloid leukemia. 2003 , 40, 62-68	2
573	Clinical decisions for chronic myeloid leukemia in the imatinib era. 2003 , 40, 98-103	3
572	Chronic myeloproliferative disorders. 571-598	8
571	Immunopolymer Lipid Nanoparticles for Delivery of Macromolecules to Antigen-Expressing Cells.. 2020 , 3, 8481-8495	2
570	Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.	2
569	Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.	1
568	The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia.	2
567	Hematologic malignancies. 2001 , 8, 189-91	134
566	Practical implications of the availability of effective drugs to treat sepsis. 2001 , 7, 345-6	1
565	KIT (CD117) immunostaining and treatment with STI-571. 2001 , 8, 304	3

564	An Integrated Mechanistic Model of Pan-Cancer Driver Pathways Predicts Stochastic Proliferation and Death.	4
563	Tunneling nanotubes contribute to the stroma-mediated imatinib resistance of leukemic cells.	3
562	MYC Functions as a Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies.	1
561	The immunogenic potential of recurrent cancer drug resistance mutations: an in silico study.	1
560	FAM111B enhances proliferation of KRAS-driven lung adenocarcinoma by degrading p16. 2020 , 111, 2635-2646	8
559	Therapeutic intent and misconception in early-phase clinical trials in the gynecologic malignancies. 2010 , 20, 311-2	1
558	TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. 2001 , 108, 523-6	65
557	Azathioprine: old drug, new actions. 2003 , 111, 1122-4	67
556	Azathioprine: old drug, new actions. 2003 , 111, 1122-1124	143
555	Stable expression of small interfering RNA sensitizes TEL-PDGFR to inhibition with imatinib or rapamycin. 2004 , 113, 1784-1791	49
554	Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. 2006 , 116, 2633-42	81
553	Treatment for chronic myelogenous leukemia: the long road to imatinib. 2007 , 117, 2036-43	76
552	Applying the discovery of the Philadelphia chromosome. 2007 , 117, 2067-74	83
551	Following the cytokine signaling pathway to leukemogenesis: a chronology. 2008 , 118, 3564-73	9
550	Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. 2009 , 119, 1727-40	205
549	Many cytokines are very useful therapeutic targets in disease. 2008 , 118, 3533-6	104
548	Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address. 2008 , 118, 3798-801	8
547	Trio receives Lasker Foundation Clinical Award for breakthroughs in leukemia treatment. 2009 , 119, 2863-2865	3

546	HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. 2010 , 120, 3578-93	153
545	Hunk is required for HER2/neu-induced mammary tumorigenesis. 2011 , 121, 866-79	23
544	Molecular genetics of B-precursor acute lymphoblastic leukemia. 2012 , 122, 3407-15	165
543	Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. 2013 , 123, 3459-71	49
542	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. 2016 , 126, 3207-18	144
541	Treatment-free remission in CML: who, how, and why?. 2017 , 2017, 102-109	46
540	Is going for cure in chronic myeloid leukemia possible and justifiable?. 2012 , 2012, 122-128	20
539	Prognostic and Predictive Factors and Targets for Therapy in Breast Cancer. 2002 , 93-124	8
538	Sonic hedgehog-dependent emergence of oligodendrocytes in the telencephalon: evidence for a source of oligodendrocytes in the olfactory bulb that is independent of PDGFR signaling. 2001 , 128, 4993-5004	89
537	Collaboration for rare disease drug discovery research. 2014 , 3, 261	15
536	Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy. 2018 , 16, e2002930	28
535	Incorporating molecular tools into early-stage clinical trials. 2008 , 5, e21	8
534	Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. 2006 , 1, e18	188
533	Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. 2010 , 5, e8919	19
532	Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. 2010 , 5, e13186	21
531	Functional characterization of human cancer-derived TRKB mutations. 2011 , 6, e16871	31
530	Cambogin is preferentially cytotoxic to cells expressing PDGFR. 2011 , 6, e21370	13
529	Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. 2012 , 7, e39412	12

528	Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. 2012 , 7, e43437	18
527	Counting highly cited papers for university research assessment: conceptual and technical issues. 2012 , 7, e47210	15
526	Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine. 2013 , 8, e77495	8
525	ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer. 2013 , 8, e83673	19
524	FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. 2014 , 9, e89388	42
523	Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. 2015 , 10, e0125021	14
522	Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats. 2015 , 10, e0131192	27
521	MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. 2015 , 10, e0143333	19
520	Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. 2016 , 11, e0166185	3
519	Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy. 2017 , 12, e0179700	3
518	The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice. 2017 , 12, e0185704	8
517	Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing. 2017 , 12, e0189651	19
516	Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes. 2012 , 179-85	2
515	Imatinib Mesylate (STI 571) [A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML). 2003 , 46, 85-89	1
514	Ethnic Differences in Hematologic Toxicity from Imatinib in Patients with Gastrointestinal Stromal Cell Tumor (GIST): Coincidence or a Real Phenomenon. 2019 , 3, 182-185	1
513	miR-155 effectively induces apoptosis in K562 Philadelphia positive cell line through upregulation of p27kip1. 2017 , 7, 109-114	7
512	Very Late Relapse of Chronic Myelogenous Leukemia Following Stem Cell Transplant. 2015 , 1,	1
511	Karyotype abnormalities and their clinical significance in a group of chronic myeloid leukemia patients treated with hematopoietic stem cell transplantation. 2007 , 125, 246-9	1

510	Incidence of spontaneous subdural hematoma in incident cases of pulmonary arterial hypertension: a registry of cases occurring over a five-year period. 2015 , 41, 101-2	2
509	Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response. 2011 , 47, 313-322	4
508	A chemoproteomic method for identifying cellular targets of covalent kinase inhibitors. 2016 , 7, 148-53	6
507	HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells. 2015 , 6, 19-29	14
506	The combinatorial complexity of cancer precision medicine. 2014 , 1, 504-9	33
505	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. 2013 , 4, 772-84	15
504	Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 mutations and review of the literature. 2017 , 8, 68950-68963	52
503	A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors. 2016 , 7, 58234-58243	6
502	The reliable assurance of detecting somatic mutations in cancer-related genes by next-generation sequencing: the results of external quality assessment in China. 2016 , 7, 58500-58515	10
501	Targeting binding partners of the CBF β SSMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia. 2016 , 7, 66255-66266	4
500	A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. 2016 , 7, 65171-65184	16
499	Role of Pten in leukemia stem cells. 2010 , 1, 156-160	30
498	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. 2017 , 8, 23061-23072	10
497	Recurrent fusion RNA DUS4L-BCAP29 in non-cancer human tissues and cells. 2017 , 8, 31415-31423	24
496	Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway. 2018 , 9, 3267-3277	10
495	Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. 2011 , 2, 245-50	36
494	Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells. 2014 , 5, 8188-201	28
493	Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia. 2014 , 5, 9564-76	29

492	Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. 2018 , 9, 21758-21769	2
491	Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. 2018 , 9, 22158-22183	2
490	NUAK2: an emerging acral melanoma oncogene. 2011 , 2, 695-704	15
489	Identification and characterization of RET fusions in advanced colorectal cancer. 2015 , 6, 28929-37	73
488	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. 2015 , 6, 26388-99	8
487	Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression. 2015 , 6, 20801-12	50
486	Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice. 2012 , 3, 261-6	17
485	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. 2015 , 6, 26886-94	38
484	A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation. 2015 , 6, 29347-56	41
483	The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. 2016 , 7, 2721-33	13
482	Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. 2016 , 7, 33016-24	24
481	Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. 2013 , 4, 715-28	77
480	Epigenomics in cancer management. 2010 , 2, 255-65	20
479	Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. 2009 , 13, 283-96	11
478	Tyrosine Kinase Inhibitor-Induced Pulmonary Arterial Hypertension. 2018 , 17, 69-74	3
477	Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy-free Era. 2019 , 26, 1002-1018	6
476	Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform. 2016 , 22, 3109-23	33
475	Personalization of targeted therapy in advanced thyroid cancer. 2014 , 15, 190-202	14

474	Achievements in Cancer Research and its Therapeutics in Hundred Years. 2019 , 19, 1545-1562	0
473	Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. 2010 , 10, 111-5	22
472	[Imatinib mesylate as a novel therapeutic drug for systemic rheumatic diseases]. 2007 , 30, 165-73	1
471	[Imatinib]. 2009 , 32, 77-84	2
470	Integrating radiomics into clinical trial design. 2019 , 63, 339-346	5
469	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. 2016 , 13, 87-100	17
468	Identification of Activated RRAS2 in Tongue Carcinoma Cell Line. 2006 , 11, 121-126	1
467	Imatinib, The Magic Bullet for Treatment of Blood Cancer. 8,	0
466	Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. 2006 , 12, 1583-90	13
465	Designing proliferating cell population models with functional targets for control by anti-cancer drugs. 2013 , 18, 865-889	14
464	Molecularly-targeted Strategy and NF- κ B in lymphoid malignancies. 2013 , 53, 185-95	12
463	Therapeutic prevention of colorectal carcinogenesis. 2011 , 10, 13	1
462	Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea. 2013 , 2, 156-61	10
461	Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management. 2019 , 2, 36	2
460	A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets. 2016 , 48, 1120-9	7
459	Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice. 2012 , S5,	7
458	Detection of Single Base Mutation Causing Drug-resistance in Leukemia Gene by PNA-directed Clamping PCR. 2010 , 31, 2077-2080	5
457	Site-selective Cleavage of RNA at Two Sites by Tandem DNzyme and its Detection by Mass Spectrometry for Genotyping of SNP. 2013 , 34, 3543-3544	1

456	Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. 2012 , 34, 352-5	14
455	Studying Side Effects of Tyrosine Kinase Inhibitors in a Juvenile Rat Model with Focus on Skeletal Remodeling.	2
454	Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. 2009 , 133, 568-79	37
453	The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. 2004 , 128, 538-43	55
452	Imatinib resistance: obstacles and opportunities. 2006 , 130, 669-79	44
451	Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of Seliciclib. 2013 , 7, 4	9
450	Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST). 2016 , 8, e848	5
449	An Isogenic Cell Line Panel for Sequence-Based Screening of Targeted Anti-Cancer Drugs.	
448	Liquid Biopsies for Molecular Biology-Based Radiotherapy. 2021 , 22,	
447	Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis. 2021 ,	11
446	Concurrence of imatinib-induced massive pleural/pericardial effusion and Campylobacter bacteremia in an adolescent with chronic myeloid leukemia. 2022 , 28, 103-107	0
445	CLIP-170S is a microtubule +TIP variant that confers resistance to taxanes by impairing drug-target engagement. 2021 , 56, 3264-3275.e7	0
444	An Engineered Specificity of Anti-Neoplastic Agent Loaded Magnetic Nanoparticles for the Treatment of Breast Cancer. 2021 , 13,	
443	The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML). 2021 , 16, 448-454	1
442	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. 2021 ,	11
441	Fluorescent Biosensor for CrkII Phosphorylation by the Abl Tyrosine Kinase. 2001 , 992-993	
440	Résistance clinique au STI571 : implication du gène bcr-abl lui-même ?. 2001 , 17, 1192-1193	
439	Imatinib. 2001 , 23,	

438 BCR/ABL Fusion Proteins.

437 Chronic Myelogenous Leukemia: Prognosis and Current Status of Treatment. **2002**, 519-524

436 Chronic Myelogenous Leukemia. **2003**, 47-56

435 Antineoplastische Therapie. **2003**, 553-632

434 Systemic Strategies for Tumor Targeting. **2003**, 136-144

433 Chronische myeloische Leukämie und andere chronische myeloproliferative Erkrankungen. **2003**, 249-267

432 Molecular Therapeutics in Prostate Cancer. **2003**, 495-515

2

431 Donor Leukocyte Infusions. **2003**, 287-310

430 Tumorerkrankungen. **2003**, 197-279

429 In Silico Proteomics. **2003**, 193-222

428 Sarcoma. **2003**, 21, 637-53

1

427 Interferons: therapy for cancer. **2003**, 301-327

426 Minimal Residual Disease in Allogeneic Recipients. **2003**, 343-353

425 Imatinib (STI571) for the Treatment of Chronic Myelogenous Leukemia (CML). **2003**, 109-116

424 Cytogenetics for Treatment Stratification in De Novo Adult Acute Myeloid Leukemia. **2003**, 366-376

423 Abl in Cell Signaling. **2003**, 249-256

422 Chronic Myelogenous Leukemia. **2003**, 213-230

421 Chronische myeloische Leukämie. **2004**, 1953-1973

- 420 Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia. **2004**, 25-45
- 419 Genetische Grundlagen der Kanzerogenese. **2004**, 75-145 1
- 418 Clinical Pharmacology Overview. **2004**, 111-127 1
- 417 The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. **2004**, 24, 113-117
- 416 Opportunities for Targeted Molecular Therapy for Prostate Cancer. **2004**, 631-652
- 415 Molecular Pathology of Hematological Malignancies. **2004**, 239-277
- 414 Exposure-Response Relationship of Anticancer Agents. **2004**, 523-537
- 413 Phase I Trial Design and Methodology for Anticancer Drugs. **2004**, 351-362
- 412 Myeloid Malignancies.
- 411 Cancer Drug Development in the Modern Era. 1
- 410 Overview of molecular target-based drugs. **2006**, 21, 18-23 2
- 409 PRECLINICAL TESTING AND VALIDATION OF NOVEL ANTICANCER AGENTS. **2006**, 233-248
- 408 Barriers to Successful Management of Breast Cancer. **2006**, 333-363
- 407 SURROGATE END POINTS AND BIOMAKERS FOR EARLY TRIALS OF NOVEL ANTICANCER AGENTS. **2006**, 249-262 0
- 406 Angiogenesis Inhibitors in Prostate Cancer. **2006**, 127-141
- 405 Early Intensification of Therapy. **2006**, 149-156
- 404 Chronische myeloproliferative Erkrankungen (CMPE). **2007**, 377-400
- 403 Drug Eruption Induced by Imatinib Mesylate (Glivec). **2007**, 69, 501-504

402 4. ??????. **2007**, 38, 387-391

401 FLT3: A Prototype Receptor Tyrosine Kinase Target in AML. **2007**, 247-261

400 Overview of Existing Therapies. **2007**, 1-17

399 Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia. **2008**, 83-104

398 Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. **2008**, 317-365

397 Mechanisms of DNA Double-Strand Break Repair in Hematopoietic Homeostasis and Oncogenesis. **2008**, 81-120

396 BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients. **2008**, 127-150

395 Les autres inhibiteurs tyrosine kinase de KIT ou de la voie AKT. **2008**, 117-130

394 Gastrointestinal Stromal Tumors. **2008**, 2087-2095

393 Systemic Therapy. **2008**, 449-483

392 De Gruyter. **2008**, 80,

391 Modeling Human Philadelphia Chromosome-Positive Leukemia in Mice. **2008**, 157-177

390 Therapeutic Targeting of the Melanoma Stem Cell Population. **2008**, 83-98

389 Comprehensive Genomic Profiling for Biomarker Discovery for Cancer Detection, Diagnostics and Prognostics. **2009**, 1-17

388 Stem Cells in Leukemia and Other Hematological Malignancies. **2009**, 111-136

387 Natural History of Cancer. **2009**, 1214-1223

386 Targeted Approaches to Drug Development. **2009**, 57-98

385 Retroperitoneale Weichteiltumoren. **2009**, 749-763

- 384 Large Cell Lung Cancer Complicated with Chronic Myelogenous Leukemia. **2009**, 49, 844-846
- 383 The Molecular Biology of Kidney Cancer and Its Clinical Translation into Treatment Strategies. **2009**, 79-97
- 382 Molecular Mechanisms of Hepatocellular Carcinoma: Insights to Therapy. **2009**, 109-130
- 381 Hämatologie. **2009**, 461-570
- 380 Infant Leukemias. **2009**, 403-416 1
- 379 Genomic Identification of Significant Targets in Brain Cancer. **2009**, 395-413
- 378 Leukemias. **2009**, 536-540
- 377 Molecular Biology of Cancer. **2009**, 1-26
- 376 Role of RNA Interference in Understanding the Molecular Basis of Cancer. **2010**, 4-20
- 375 Full Intensity and Reduced Intensity Allogeneic Transplantation in AML. **2010**, 11-27
- 374 The Role of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia Patients in the Era of Tyrosine Kinase Inhibitors. **2010**, 53-74
- 373 Pathogenesis of Malignant Melanoma. **2010**, 55-64
- 372 Multiple Endocrine Neoplasia Type 2. **2010**, 2742-2758
- 371 Discovery of a Lung Cancer Oncogene, EML4-ALK, and Its Clinical Application. **2010**, 50, 889-893
- 370 Targeted Therapy in the Treatment of Orbital and Periorbital Malignancies. **2010**, 187-193
- 369 Precursor B-Cell Acute Lymphoblastic Leukemia. **2010**, 287-307
- 368 Well-Differentiated Thyroid Follicular Carcinoma. **2010**, 73-93
- 367 Chronic Myeloid Leukemia: Pathophysiology and Therapeutics. **2010**, 139-153

- 366 DNA Biomarkers in the Diagnosis and Management of Cancer. **2010**, 165-184
- 365 Risk Factors and Genetical Characterization. **2011**, 27-63
- 364 Pharmacology of Acute Lymphoblastic Leukemia Therapy. **2011**, 127-144
- 363 Promising Targeted Agents. **2011**, 193-214
- 362 Use of Flow Cytometry to Study Drug Target Inhibition in Laboratory Animals and in Early-Phase Clinical Trials. 151-168
- 361 Targeted Therapeutics in Cancer Treatment. **2011**, 403-461
- 360 High-Grade Astrocytomas. **2011**, 195-232
- 359 Protein Kinase Inhibitors. **2011**, 319-330
- 358 Leucmie myéloïde chronique. **2011**, 745-756
- 357 Encyclopedia of Cancer. **2011**, 1808-1811
- 356 Cardiac Involvement in Hypereosinophilic Syndrome. **2011**, 414-416
- 355 Induction Therapy in Adult Acute Lymphoblastic Leukemia. 193-216
- 354 Pathophysiology of Chronic Myeloid Leukemia. 259-270
- 353 Resistance to Targeted Therapies As a Result of Mutation(s) in the Target. **2011**, 1-31
- 352 Molecular Diagnosis of Hematopoietic Neoplasms. **2011**, 1415-1440
- 351 Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients. **2011**, 71, 210 1
- 350 Non-Cytogenetic Markers and their Impact on Prognosis. 56-76
- 349 Therapy of Newly Diagnosed and Chronic-Phase Chronic Myeloid Leukemia. 271-280 0

- 348 KIT as a Therapeutic Target for Melanoma. **2012**, 43-61
- 347 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
- 346 Principles of Cancer Chemotherapy in Children. **2012**, 3169-3172
- 345 Changing Paradigms in Cancer Clinical Trials. **2012**, 227-246
- 344 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61
- 343 Chromosomal abnormalities in leukemias. **2012**, 15, 105-113
- 342 Lymphoid Lesions. **2012**, 226-245
- 341 Melanoma and Other Skin Cancers. **2012**, 439-468
- 340 Recent Advances of Management for Chronic Myeloid Leukemia. **2012**, 83, 718 2
- 339 Hematopoietic Malignancies. **2012**, 1371-1396
- 338 From Transplant to Tablets: A paradigm shift in Oncology. **2012**, 12, 402-5 0
- 337 Chronic Myeloid Leukaemia: A paradigm for malignancy or just a strange disease?. **2012**, 12, 422-8 1
- 336 Future Directions in Aggressive Lymphomas. **2013**, 173-189
- 335 Cancer Is a Problem of Developmental Biology: Maturation Arrest and the Hierarchical Model of the Origin of Cancer from Stem Cells. **2013**, 429-440
- 334 TYPES OF DNA DAMAGE. **2013**, 115-118
- 333 Molecular Diagnostic Techniques. **2013**, 3-16
- 332 The Reciprocal Interaction of Small Molecule Protein Kinase Inhibitors and ATP-Binding Cassette Transporters in Targeted Cancer Therapy.
- 331 . **2013**, 125-128

330 Kinase Dysfunction and Kinase Inhibitors. 197-203

329 EML4-ALK Fusion Gene and Therapy with ALK-Targeted Agents in Non-Small Cell Lung Cancer. **2013**, 449-472

328 Domain Specific Targeting of Cancer. **2014**, 299-310

327 Treatment options for tyrosine kinase inhibitor-resistant chronic myeloid leukemia. **2013**, 78-96

326 The Effect of Treatment for Chronic Myeloid Leukemia: Meta- Analysis. **2013**, 30, 304-319

325 DNA Microarray Assay Helps to Identify Functional Genes Specific for Leukemia Stem Cells. **2013**, 2013, 1-5 1

324 Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms. **2014**, 255-272

323 Anticancer Clinical Pharmacology Overview. **2014**, 141-157 1

322 Defining the Starting Dose: Should It Be mg/kg, mg/m², or Fixed?. **2014**, 69-87

321 ExposureResponse Relationships of Anticancer Agents: Application in Drug Development and Drug Label. **2014**, 747-762 1

320 The Role of Phase III Trials in Modern Drug Development. **2014**, 763-783

319 Encyclopedia of Cancer. **2014**, 1-5

318 Regional Evaluation of Tolerability and Efficacy of Imatinib Mesylate in Patients with Chronic Phase CML in Mashhad (Iran, Southwest Asia). **2014**, 06, 900-907

317 Retroperitoneale Weichteiltumoren. **2014**, 797-812

316 Strategic therapeutic approaches to overcome emerging dual SRC/ABL kinase inhibitors resistances in chronic phase Ph positive chronic myeloid leukemia. **2014**, 6, 8-15

315 Implementation of Exome Sequencing Assay. **2015**, 225-240

314 The Cancer Cell-Kill Paradigm and Beyond. **2015**, 101-128

313 Imatinib-associated massive upper gastrointestinal hemorrhage and hepatic encephalopathy in a child with Philadelphia positive acute lymphoblastic leukemia: A case report and review of the literature. **2014**, 3, 234-5

312 Targeting the PI3 Kinase-mTOR Signaling Pathway in AML. **2015**, 363-370

311 Pharmacogenetics and Antineoplastic Therapies. **2015**, 275-305

310 Pharmacogenomics for Oral Disease. **2015**, 363-388

309 Encyclopedia of Cancer. **2015**, 1-4

308 From Bench to Bedside with Targeted Therapies. **2015**, 621-634.e2

307 Therapeutic targets in gastrointestinal stromal tumors. **2015**, 4, 25

1

306 Ovarian Cancer. **2015**, 393-433

305 Therapeutic Implications of Cancer Stem Cell: Challenges and Opportunities in Translational Studies. **2015**, 533-553

304 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

303 Molekulare Grundlagen der malignen Transformation. **2015**, 1-16

302 Role of Stem Cell Elements in Chronic Myeloid Leukemia. **2015**, 3,

301 Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. **2015**, 6, 25452-65

3

300 Clinical Implications of Microarray in Cancer Medicine. **2015**, 11, 150-158

1

299 Molecular Targeted Anticancer Drugs. **2016**, 175-238

298 Transcription Factors Synergistically Activated at the Crossing of the Restriction Point between G1 and S Cell Cycle Phases. Pathologic Gate Opening during Multi-Hit Malignant Transformation. **2016**, 3,

297 Targeted Cancer Therapy. **2016**, 78, 221-228

296 Encyclopedia of Cancer. **2016**, 1059-1063

295 Current approach for chronic myeloid leukemia treatment with tyrosin kinase inhibitors. **2016**, 10, 120-126

294 Oncogenes and the Initiation and Maintenance of Tumorigenesis. **2017**, 143-157

293 Systems Chemical Biology: Integrating Medicinal Chemistry and Systems Biology for Drug Discovery. **2017**, 481-494

292 Inhibition of Tumor Angiogenesis in GIST Therapy. **2017**, 1-13

291 Targeted Therapy and Precision Medicine. **2017**, 183-200

1

290 Encyclopedia of Cancer. **2017**, 2205-2208

289 Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection. **2017**, 34, 362-364

1

288 Gene Fusions. **2018**, 137-151

287 Precision Medicine Based on Next Generation Sequencing and Master Controllers. **2018**, 1-35

286 Oncogene Addiction in Chronic Myeloid Leukaemia. 1-9

0

285 The cancer-mutation network and the number and specificity of driver mutations.

284 Noncanonical Notch Signaling. **2018**, 35-53

1

283 Tyrosine Kinases, microRNAs, Epigenetics: New Insights in the Mechanisms of Leukemogenesis. **2018**, 11-25

282 Pharmacotherapeutic Options for Philadelphia Chromosome- Positive CML. **2018**, 7, 49-58

281 Historical Perspectives. **2019**, 15-59

280 Drug Induced Pulmonary Arterial Hypertension. **2018**, 20, 259-264

279 Gastrointestinal Stromal Tumor (GIST): Diagnosis and Treatment. **2019**, 817-849

278 Simultaneous Determination of Imatinib and N-Desmethyl Imatinib in Rat Plasma and Tissues Using LC-MS/MS. **2019**, 15, 121-129

1

277 Inhibition of Tumor Angiogenesis in GIST Therapy. **2019**, 449-461

276 Molecular Diagnostics in Cancer: A Fundamental Component of Precision Oncology. **2019**, 5-31

275 JuLI: accurate detection of DNA fusions in clinical sequencing for precision oncology.

274 Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR/Cas9 screening.

273 [Chemotherapy-Free Treatment of Hematological Neoplasias: Dream or Reality?]. **2019**, 108, 411-418

272 Chronic Myeloid Neoplasms. **2020**, 235-251

271 Trajectories from Snapshots: Integrated proteomic and metabolic single-cell assays reveal multiple independent adaptive responses to drug tolerance in a BRAF-mutant melanoma cell line.

270 Imatinib overrides taxane resistance by selective inhibition of novel CLIP1 variant obstructing the microtubule pore. 0

269 Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms.

268 Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role. **2019**, 20, 3689-3695 1

267 Mapping the Radiogenome of Human Cancers. **2020**, 35-61

266 Paradigms in Cancer Drug Development: A Universe with Many Galaxies. **2020**, 17-44

265 Cell biological basis of tumor relapse and recurrence [A help from yeast quiescent biology and neuronal quiescent cell biology. 5, 27-34

264 Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients. **2020**, 10, 8394 0

263 Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors. **2020**, 17, 213-224 1

262 Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand. **2020**, 21, 2003-2012 0

261 A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. **2021**, 111, 106737 0

260 Understanding the impact of anticancer halogenated inhibitors and various functional groups (X = Cl, F, CF, CH, NH, OH, H) of casein kinase 2 (CK2). **2020**, 1-17 1

259 Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo. **2020**, 21, 996-1008

258 CORR Insights : Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma. **2021**, 479, 853-854

257 Computational and Biological Investigations on Abl1 Tyrosine Kinase: A Review. **2021**, 22, 38-51

2

256 Tumor Profiling. **2020**, 319-327

255 CHAPTER 15: Precision Oncology. **2020**, 345-362

0

254 Kronik Miyeloid Lēmide ĩatinib Mesilat Tedavisi.

253 Conditionally Reprogrammed Cells and Robotic High-Throughput Screening for Precision Cancer Therapy. **2021**, 11, 761986

0

252 Molecular Pathogenesis of Gastrointestinal Stromal Tumor: A Paradigm for Personalized Medicine. **2021**,

1

251 Ethics of Clinical Oncology Research. **2006**, 127-142

250 NF-Ĕ in Human Cancers. **2006**, 131-146

249 Chronische myeloproliferative Erkrankungen. **2005**, 1108-1123

248 Experimentelle Therapie und somatische Gentherapie von Krebs. **2005**, 258-267

247 Chronische myeloproliferative Erkrankungen. **2006**, 724-731

246 Antineoplastische Therapie. 561-638

245 Anti-angiogenesis agents. **2006**, 167-183

244 EPITHELIAL CELL SURFACE TARGETING USING SYNTHETIC D-AMINO ACID PEPTIDES. **2006**, 179-192

243 Stable expression of small interfering RNA sensitizes TEL-PDGĔbetaR to inhibition with imatinib or rapamycin. **2004**, 113, 1784-91

20

242 References. 301-319

241 Chronic Myelogenous Leukemia. **2006**, 789-793

- 240 Principles of Medical Management. **2006**, 93-100
- 239 The Biology and Genetics of Melanoma. **2006**, 265-290
- 238 Cancer Chemotherapy. **2006**, 543-557
- 237 Tyrosine Kinase Inhibitors. **2007**, 477-508
- 236 Somatic Alterations in Prostate Cancer Progression. **2007**, 269-283
- 235 The Cell Cycle. **2008**, 3-32
- 234 Preclinical Development of Molecularly Targeted Agents in Oncology. **2008**, 707-722 0
- 233 Targeted Therapy in Melanoma. **2008**, 183-211
- 232 Validating Immunohistochemical Staining for KIT (CD117). **2003**, 119, 0-0 1
- 231 Targeted lung cancer therapy: what have we learned from gefitinib?. **2005**, 2, 1-2
- 230 Myeloproliferative Erkrankungen. 292-317
- 229 Retroperitoneale Weichteiltumoren. **2007**, 619-632
- 228 Therapeutic Strategies and Concepts of Cure in CML. **2007**, 201-218
- 227 Clinical Features of CML. **2007**, 59-74
- 226 Treatment with Tyrosine Kinase Inhibitors. **2007**, 103-113
- 225 Experimentelle Therapie und somatische Gentherapie von Krebs. **2007**, 292-301
- 224 Retroperitoneale Weichteiltumoren. **2014**, 797-812 0
- 223 Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors. **2003**, 40, 11-14

222	Cytogenetic studies in patients on imatinib. 2003 , 40, 50-55	7
221	The cytogenetic response as a surrogate marker of survival. 2003 , 40, 56-61	2
220	Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. 2003 , 40, 80-82	
219	Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials. 2003 , 40, 92-97	
218	Fusion Transcript Detection from RNA-Seq using Jaccard Distance. 2020 ,	1
217	Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm. 2020 , 3, 147-156	
216	Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity. 2020 , 20, 1966-1980	0
215	Renal cell carcinoma and the use of sorafenib. 2006 , 2, 87-98	11
214	The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations. 2007 , 118, 253-61	4
213	The cancer treatment revolution. 2007 , 118, 317-23	2
212	Chronic Myeloid Leukaemia in The 21st Century. 2007 , 76, 8-17	14
211	Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevec trade mark). 2008 , 4, 163-87	24
210	Origins of cancer therapy. 2001 , 74, 391-8	50
209	Disruption of Survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571. 2008 , 6, 603-610	5
208	Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. 2007 , 1, 433-48	17
207	Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. 2007 , 1, 121-7	10
206	Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. 2007 , 1, 129-38	5
205	Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia. 2011 , 3, 65-78	3

204	Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases. 2007 , 2, 239-47	2
203	Role of Pten in leukemia stem cells. 2010 , 1, 156-60	20
202	Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. 2011 , 1, 604-17	26
201	Angiogenesis and melanoma - from basic science to clinical trials. 2011 , 1, 852-68	21
200	Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia. 2005 , 1, 1-12	2
199	New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. 2009 , 1, 44-60	2
198	A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. 2012 , 5, 77-83	12
197	The President's Address: Clinical Investigation is a Pathway to Discovery. 2012 , 123, 1-8	1
196	Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival. 2009 , 5, 223-8	2
195	Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era. 2013 , 3, 191-200	8
194	Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. 2012 , 30, S86-96	10
193	Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML. 2015 , 5, 354-62	4
192	The Effects of Imatinib Mesylate on Cellular Viability, Platelet Derived Growth Factor and Stem Cell Factor in Mouse Testicular Normal Leydig Cells. 2016 , 17, 82-7	2
191	Cutaneous complications of molecular targeted therapy used in oncology. 2016 , 9, 19-25	8
190	Drug Development Against Metastatic Cancers. 2017 , 90, 119-123	4
189	Association between Altered Expression and Genetic Variations of Transforming Growth Factor β Smad Pathway with Chronic Myeloid Leukemia. 2018 , 12, 14-22	1
188	Identifying Cancer Patients at Risk for Heart Failure Using Machine Learning Methods. 2019 , 2019, 933-941	1
187	[Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia]. 2016 , 37, 110-4	0

186	[Clinical observation of chromosomal abnormalities in Ph negative cells of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors]. 2016 , 37, 412-6	
185	[Prognostic significance of early molecular response after second-line treatment with dasatinib of chronic myeloid leukemia patients]. 2019 , 40, 608-611	
184	An updated account on molecular heterogeneity of acute leukemia. 2021 , 11, 22-43	1
183	Application of a Successful Germ Cell Tumor Paradigm to the Challenges of Common Adult Solid Cancers. 2021 , 12,	1
182	Imatinib augments standard malaria combination therapy without added toxicity. 2021 , 218,	2
181	Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor- β . 2021 , 288, 120171	1
180	Genetic fusions favor tumorigenesis through degran loss in oncogenes. 2021 , 12, 6704	2
179	Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia.. 2021 , 10,	1
178	A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity : A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias. 2021 , 12, 749361	0
177	Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor. 2021 , 11, 772862	2
176	Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis. 2021 , 10, 8741	1
175	Analysis of protein phosphorylation combining capillary electrophoresis with ATP analog labeling technique. 2021 ,	0
174	Perspektivenwechsel: Ein Wirkstoff ff mehrere Krebserkrankungen.	
173	Helping Leukemia Cells to Die with Natural or Chemical Compounds Through H2O2 Signaling. 2021 , 1-14	1
172	The tyrosine kinase inhibitor Bosutinib does not inhibit angiotensin II-induced abdominal aortic aneurysm: Validation of the importance of PDGFR and c-Kit tyrosine kinases by Imatinib.. 2022 , 340, 68-69	
171	Comparative Gene Expression Analysis Reveals Similarities and Differences of Chronic Myeloid Leukemia Phases.. 2022 , 14,	0
170	A novel imatinib-upregulated long noncoding RNA plays a critical role in inhibition of tumor growth induced by Abl oncogenes.. 2022 , 21, 5	0
169	Intelligent drug design come of age: STI571 as the start a of a new era in cancer research and treatment. 2001 , 3, 229-230	

168	TRAIL/Apo-2L death signaling pathway and molecular targeting agents: implications for chemoresistance. 2001 , 3, 284-291	
167	Prospects for Targeted Kinase Inhibition in Cancer: Neurofibromatosis Type 1-Related Neoplasia. 2021 ,	
166	Imatinib augments standard malaria combination therapy without added toxicity. 2021 , 218,	3
165	Epithelial-mesenchymal transition and HO signaling ⁺ a driver of disease progression and a vulnerability in cancers.. 2022 ,	0
164	Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice.. 2022 , 27, 183-190	1
163	Current State of Pediatric Cardio-Oncology: A Review.. 2022 , 9,	0
162	Recent advancements in understanding the genetic involvement of alpha-1 antitrypsin deficiency associated lung disease: a look at future precision medicine approaches.. 2022 , 1-10	
161	Helping Leukemia Cells to Die with Natural or Chemical Compounds Through H2O2 Signaling. 2022 , 551-564	
160	Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort.. 2022 , 6, e2100232	1
159	Targeted Therapy in Leukaemia, Lymphoma and Myeloma.. 2022 , 12,	0
158	Whole-genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study.. 2022 ,	0
157	JAFFAL: detecting fusion genes with long-read transcriptome sequencing.. 2022 , 23, 10	2
156	PET imaging of Gastrointestinal Stromal Tumors (GIST). 2022 ,	
155	Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis.. 2022 , 39, 29	
154	Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition.. 2021 , 101525	0
153	Successful treatment of imatinib-induced periorbital edema with a sodium-glucose cotransporter-2 inhibitor.. 2022 , 1	0
152	The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience.. 2022 , 10, 820586	1
151	Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry.. 2022 ,	0

- 150 Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens.. **2022**, 12, 290-292 1
- 149 Methoden klinischer Prüfung in der Onkologie. **2021**, 1-53
- 148 Patient-Derived In Vitro and In Vivo Models of Cancer.. **2022**, 1361, 215-233 0
- 147 C11orf21, a novel RUNX1 target gene, is down-regulated by RUNX1-ETO. **2022**, 2, 100047 1
- 146 Synthesis of ponatinib analogues as novel inhibitors of leukemia stem cells.. **2022**,
- 145 Ethical Considerations for Phase I Trials in Oncology.. **2022**, JCO2102125 0
- 144 Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.. **2022**, 101, 1015
- 143 Anticancer Activity of Erianin: Cancer-Specific Target Prediction Based on Network Pharmacology.. **2022**, 9, 862932 1
- 142 Targeting Reductive Metabolic Shifts by T315I Mutation in BCR-ABL Myeloid Leukemia for Therapy. 0
- 141 FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF- κ B signaling activation.. **2022**, 41, 82 0
- 140 Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB.. **2022**, 13, 8881-8892
- 139 A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.. **2022**, e1616 0
- 138 A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo.. **2022**, 14, eabm0306 2
- 137 Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines.. **2022**, 112869 0
- 136 Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.. **2022**, JCO2102767 7
- 135 LENS - Landscape of Effective Neoantigens Software.
- 134 Stimuli-controllable iron oxide nanoparticle assemblies: Design, manipulation and bio-applications.. **2022**, 345, 231-274 0
- 133 Low-dose dasatinib: when less can be more. **2021**, 8, e867-e868

- 132 The TKI Era in Chronic Leukemias.. **2021**, 13, 2
- 131 The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018. **2021**, 0
- 130 Molecular Characteristics of m6A Regulators and Tumor Microenvironment Infiltration in Soft Tissue Sarcoma: A Gene-Based Study.. **2022**, 10, 846812 0
- 129 Bone marrow. 813-942
- 128 DataSheet_1.pdf. **2020**,
- 127 Table_1.xlsx. **2020**,
- 126 Table_2.xlsx. **2020**,
- 125 Table_3.xlsx. **2020**,
- 124 Table_4.xlsx. **2020**,
- 123 Table_5.xlsx. **2020**,
- 122 Table_6.xlsx. **2020**,
- 121 Table_7.xlsx. **2020**,
- 120 Table_8.xlsx. **2020**,
- 119 Data_Sheet_1.zip. **2019**,
- 118 Data_Sheet_2.csv. **2019**,
- 117 Data_Sheet_3.ZIP. **2019**,
- 116 Table_1.XLSX. **2019**,
- 115 Table_2.XLSX. **2019**,

114	Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults with CML in the TKI Era.. 2022,	0
113	Characterization of anticancer drug resistance by Reverse Phase Protein Array: new targets and strategies.. 2022,	0
112	PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.. 2021, 11, 6042-6059	
111	Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.. 2022, 10, 872729	0
110	Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases.. 2022, e202200983	1
109	Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset Of Resistance Mutations in Kinases.	
108	Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience.. 2022, 1-11	
107	The translational challenges of precision oncology.. 2022,	3
106	The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.. 2022, 238, 114442	0
105	Systemic Diseases. 2016, 739-804	
104	Kinase inhibitors: An overview. 2022, 1-22	
103	An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer Drugs. 2022, 104437	
102	A Literature Review of the Janus Kinase Inhibitors Used in the Treatment of Auto-Immune Dermatological Conditions. 2022, 13, 37-42	
101	An update on novel multiple myeloma targets.	0
100	Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia. 2022, 27, 3220	0
99	Mechanism of treatment-free remission in patients with chronic myeloid leukemia revealed by a computational model of CML evolution.	0
98	Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia.	0
97	Genomic biomarkers to guide precision radiotherapy in prostate cancer. 2022, 82,	0

96	Integrative signatures of signaling pathway response increase robustness and accuracy of pathway predictions.		
95	Learning about allosteric drugs and ways to design them. 2022 , 167692		1
94	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2022 , 386, 2399-2411	59.2	1
93	miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors. 2022 , 3, 373-384		
92	Understanding Myocardial Metabolism in the Context of Cardio-Oncology. 2022 , 18, 415-424		
91	THOC5 regulates human osteoclastogenesis. 2022 , 101, 151248		
90	Microfluidics for Cancer Biomarker Discovery, Research, and Clinical Application. 2022 , 499-524		0
89	Structural variations in cancer and the 3D genome.		0
88	BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph + chronic myeloid leukemia.		3
87	Reengineering Ponatinib to Minimize Cardiovascular Toxicity. OF1-OF15		0
86	Widespread protein N-phosphorylation in organism revealed by SiO ₂ @DpaZn beads based mild-acidic enrichment method. 2022 , 123740		0
85	Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells. 2022 , 23, 7715		
84	Peptide-based targeted cancer therapeutics: Design, synthesis and biological evaluation. 2022 , 176, 106249		
83	Clinical and Molecular Evidence for c-kit Receptor as a Therapeutic Target in Neuroblastic Tumors. 2005 , 11, 380-389		7
82	Dual Inhibition of RET and FGFR4 Restrains Medullary Thyroid Cancer Cell Growth. 2005 , 11, 1336-1341		16
81	The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient. 2023 , 448-458		
80	Imatinib and Patient-Related Outcomes in Chronic Myeloid Leukemia: A Single Centric Experience. 2022 , 4,		
79	Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials. 12,		0

78	The mRNA Expression of PTEN, LEF1, JAK3, LC3 and p62/SQSTM1 Genes in Patients with Chronic Myeloid Leukemia. 2022 , 20,	
77	Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia. 2022 , 14, 1676	
76	Utilisation of semiconductor sequencing for detection of actionable fusions in solid tumours. 2022 , 17, e0246778	
75	TKI dosing for chronic phase CML : the case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day).	
74	Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.	2
73	Kjemoprevensjon av munnhulekreft. 2003 , 113,	0
72	HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells. 2023 , 21, 483-498	1
71	Clinical News Update. 2001 , 6, 211-213	0
70	Imatinib-induced cardiotoxicity: A study to evaluate cardiac functions in patients on imatinib therapy for chronic myeloid leukemia. 2022 , 13, 71	0
69	Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory. 2022 , 101, 2241-2255	0
68	Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. 2022 ,	0
67	Enantioselective semisynthesis of novel cephalotaxine esters with potent antineoplastic activities against leukemia. 2022 , 114731	0
66	Impact of neoadjuvant treatment on rectal gastrointestinal stromal tumors. 2022 , 17, e0270887	0
65	9.4 T static magnetic field ameliorates imatinib mesylate-induced toxicity and depression in mice.	2
64	Rethinking cancer targeting strategies in the era of smart cell therapeutics.	1
63	Deep morphology learning enhances ex vivo drug profiling-based precision medicine.	1
62	Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFR Wild Type GIST. 2022 , 23, 10368	0
61	circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation. 2022 , 20,	0

60	Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. 2022 , 11,	4
59	Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. 12,	0
58	A novel coumarin derivative DBH2 inhibits proliferation and induces apoptosis of chronic myeloid leukemia cells. 2022 ,	0
57	Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies. 2022 , 12,	1
56	Editorial: Translating clinical genomics and health informatics into precision oncology. 13,	0
55	Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing.	1
54	Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing.	0
53	Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia. 12,	0
52	Targeted therapy in oncology. 2022 , 222-228	0
51	Kinase Inhibitor Pulldown Assay (KIP) for Clinical Proteomics.	0
50	Cancer Genomics and Evolution. 1-30	0
49	Precision Medicine in Oncology Drug Development. 1-15	0
48	Small molecule inhibitors targeting the cancers. 2022 , 3,	0
47	Reply to Correspondence on Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase□	0
46	Reply to Correspondence on Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase□	1
45	MYC and therapy resistance in cancer: risks and opportunities. 2022 , 16, 3828-3854	0
44	Identification of proteomic landscape of drug-binding proteins in live cells by proximity-dependent target ID. 2022 ,	0
43	Principles of Medical Oncology. 1-13	0

42	Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review. 2022 , 27, 6608	0
41	Functional characterization of podia formation in normal and malignant hematopoietic cells. 2002 , 71, 425-432	5
40	RESULTS OF THE APPLICATION OF IMATINIB (GLIVEK) IN THE TREATMENT OF PATIENTS WITH CHRONIC MYELOLEUKEMIA. 2011 , 30-33	0
39	Canine gastrointestinal stromal tumours treated with surgery and imatinib mesylate: three cases (2018-2020).	0
38	Overview of the Risk of Infection Associated with Biologic and Target Therapies. 2022 , 3-15	0
37	Diverse Effects of Hypothalamic Proline-Rich Peptide (PRP-1) on Cell Death in Neurodegenerative and Cancer Diseases.	0
36	TKIs combined with chemotherapy followed by allo-HSCT in Philadelphia chromosome-positive myelodysplastic syndrome: A case report and literature review. 2022 , 101, e31874	0
35	The coming decade in precision oncology: six riddles. 2023 , 23, 43-54	1
34	A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. 2022 , 5,	0
33	Flow cytometry in the diagnosis of myelodysplastic syndromes.	0
32	The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: giant strides and ongoing challenges.	0
31	Incidence and survival of soft tissue sarcoma in England between 2013-2017, an analysis from the National Cancer Registration and Analysis Service.	0
30	Transplantation in CML in the TKI era: who, when, and how?. 2022 , 2022, 114-122	0
29	Emerging Therapeutics Agents and Recent Advances in Drug Repurposing for Alzheimer's Disease. 2022 , 101815	0
28	A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer. 2022 , 23,	0
27	Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets.	0
26	Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. 13,	0
25	Quo vadis precision oncology?.	0

- 24 Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1 β -Mediated Inflammation. ○
- 23 BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. **2023**, 480, 161-176 ○
- 22 Immunogenic Cell Death in Cancer. **2023**, ○
- 21 Melanoma with Brain Metastasis. **2023**, 1-30 ○
- 20 The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors. **2023**, 24, 2101 1
- 19 The application of RNA sequencing in precision cancer medicine. **2023**, ○
- 18 Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation. **2023**, 28, 1641 ○
- 17 Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. **2023**, 15, 664 ○
- 16 Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review. ○
- 15 Clinical Cancer Genomic Diagnostics and Modern Diagnostic Pathology. 1-13 ○
- 14 How do we trade off benefits and harms of anticancer drugs for advanced cancer patients?. **2023**, 66, 86-90 ○
- 13 Current trends in the treatment of recurrent adenocystic cancer of the salivary glands: case report. **2023**, 12, 109-115 ○
- 12 Applications of promiscuity of FDA-approved kinase inhibitors in drug repositioning and toxicity. **2023**, 465, 116469 ○
- 11 A Novel Method for Fusion Gene Detection using Both End-Fragment Sequences of Long Reads. **2022**, ○
- 10 Imatinib mitigates experimentally-induced ulcerative colitis: Possible contribution of NF- κ B/JAK2/STAT3/COX2 signaling pathway. **2023**, 321, 121596 ○
- 9 Therapeutic Drug Monitoring in Oncohematological Patients: A Fast and Accurate HPLC-UV Method for the Quantification of Nilotinib in Human Plasma and Its Clinical Application. **2023**, 11, 947 ○
- 8 Rigid Scaffolds are Promising for Designing Macrocyclic Kinase Inhibitors. ○
- 7 Precision Oncology: Evolving Clinical Trials across Tumor Types. **2023**, 15, 1967 ○

- 6 Tumor-specific activity of precision medicines in the NCI-MATCH trial. ○
- 5 Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. **2023**, 14, ○
- 4 Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response. ○
- 3 Epigenetic regulation by ASXL1 in myeloid malignancies. ○
- 2 Thérapeutique ciblée : 20 ans après ses débuts dans les sarcomes et la leucémie myéloïde chronique. **2023**, ○
- 1 An Inflection Point in Cancer Protein Biomarkers: What Was and What's Next. **2023**, 100569 ○